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ABSTRACT 
Most proteins assemble into oligomeric complexes. These supramolecular 
associations may confer many advantages to the substituents. Polyhedral capsids represent 
a common, highly symmetric nanoscale architecture in which multiple subunits self-
assemble to form a hollow three-dimensional surface which often serve as molecular 
containers or platforms for multivalent display of ligands. Capsids can be tailored to serve 
in applications such as drug delivery, biocatalysis, and materials synthesis. In this 
dissertation, I present a body of work undertaken on the Aquifex aeolicus lumazine 
synthase (AaLS) capsid to expand our knowledge of supramolecular protein associations 
and to generate capsids with novel functions. 
First, the construction and characterization of a novel nanoreactor is described. 
Using a previously established tagging system, an esterase was encapsulated in a 
laboratory-evolved variant of AaLS. Characterization of the purified complex shows an 
average loading of two esterases per capsid and an approximately 20-fold decrease in 
efficiency compared to the free esterase. This decrease is larger than most of the previously 
reported capsid-based nanoreactor systems which suggests that both the confinement 
molarity and the electrostatic environment of the capsid interior may significantly influence 
the kinetic parameters of guest enzymes. 
Second, I utilize charge complementarity to decorate the exterior of an AaLS capsid 
variant with green fluorescent protein (GFP). A new interface was engineered by   
iv 
 
negatively supercharging the five-fold symmetric capsid pores and appending a 
deca-arginine tag to the C-terminus of GFP. This interaction requires the engineered 
features of both binding partners and shows steep dependence on the buffer ionic strength, 
although it retains high affinity at physiological ionic strength. Thus, charge 
complementarity can provide a simple, powerful, and general method for designing protein 
associations de novo. 
Finally, I expand upon previous work in which a redox switch was developed to 
control capsid assembly. The original switch relies on the formation of a disulfide-bonded 
adduct between a pentameric variant of AaLS and thiophenol. I explore alterations to the 
prosthetic group structure which reveal that the three-fold symmetric interface of the 
assembled capsid is highly plastic and can tolerate a range of different adduct sizes and 
shapes. These studies also identified two new disassembly switches, providing greater 
control over the supramolecular chemistry of the AaLS capsid. 
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1.1 Supramolecular Assembly of Proteins 
 
1.1.1 Benefits of Oligomerization 
 
Studies over the last two decades have consistently demonstrated that 
oligomerization plays a crucial role in a variety of cellular pathways and functions 
including structural maintenance,1 cell division,2 gene repair,3 pathogen defense,4 and 
apoptosis,5 among others. The vast majority of proteins do not exist in their functional 
states as monomers. They assemble into supramolecular complexes containing two or more 
identical (homooligomer) or different (heterooligomer) subunits. Analysis of the Brenda 
enzyme database has shown that, for enzymes whose subunit composition is known, at 
most only one third are monomers.6 The rest are multimers with dimers and tetramers being 
the most prevalent higher order associations. Analysis of structures deposited in the PDB 
yields similar results. In both databases, homoologimers significantly outnumber 
heterooligomers.  
While supramolecular assembly in general confers a number of advantages over 
monomers such as greater stability,7 resistance to proteases,8 and enhanced enzymatic 
activity,9 homooligomerization in particular is believed to provide additional benefits.10 
The use of a single, uniform building block reduces the minimum necessary size of an 
organism’s genome. A smaller genome reduces resource expenditure during replication 
and is particularly important for viruses as they have a very limited space in which to pack 
their genetic material. Further, evolution of a single gene to achieve homooligomerization 
is likely to be faster and simpler than the same process used to achieve 
heterooligomerization of multiple gene products. Having smaller functional units is also 




production of a replacement is much less energy and resource intensive. 
Uniform building blocks also give rise to high levels of symmetry which have been 
shown to provide the most stable associations.11 They achieve this stability in two ways. 
First, highly specific interfaces, such as those typically found between homooligomers, are 
stabilized by significant complementarity in the shape and charge of these interfaces. This 
specificity gives rise to strongly directional associations which, in turn, results in highly 
symmetric assemblies. Second, highly symmetric structures have a tendency to form closed 
complexes. These complexes provide a maximum number of subunit interfaces for a given 
volume and thus maximal stability. 
In addition to improved stability, highly symmetric assemblies can benefit from 
avidity-enhanced receptor or ligand binding due to the multivalent display of the 
interacting domains on the surface of the complex.12 Maintaining multiple copies of these 
domains spread symmetrically over the assembly surface greatly increases the statistical 
likelihood of a productive collision between them and their binding partners.  
Despite the prevalence of supramolecular assemblies, the atomic level driving 
forces behind subunit association, and thus structure formation, are not completely 
understood. No generally applicable patterns of amino acid composition or secondary 
structural characteristics have been found which allow for consistently reliable prediction 
of the existence and function of protein-protein interfaces.13 However, it has been noted 
that the majority of binding free energy is usually contributed by a minority of the residues 
at the binding interface.14 Studying these hot spots, as they have come to be called, has 
greatly improved our understanding of how and why supramolecular complexes assemble. 




and function of interface associations. 
1.1.2 The Structure of Protein Interfaces 
Oligomerization interfaces are defined by their size, chemical composition, and 
surface complementarity.15 The majority of protein-protein interfaces are composed of a 
single patch with a buried surface area of 1200 – 2000 Å2. 16 However, interfaces consisting 
of multiple patches with a total area of 7000 Å2 have been reported.17 Interfaces smaller 
than 1200 Å2 typically correspond to transient associations. An area of 500 – 600 Å2 is 
generally held as the minimum surface area necessary to exclude solvent molecules from 
the binding interface.14 Interestingly, the amount of free energy per unit surface area is 
largest for smaller interfaces, approximately 13 cal mol-1 Å-2, and decreases linearly with 
total buried surface area until leveling off at a minimum of 4 cal mol-1 Å-2 at 2000 Å2. This 
correlation suggests that smaller interfaces have a higher density of hot spots.18 
Hot spots are regions of protein-protein interfaces containing residues which 
contribute a significant amount of energy to the free energy of binding of the interface. 
More specifically, these residues were originally identified as those whose mutation to 
alanine increased the change in free energy of binding by 2.0 kcal/mol or more.14 Bulk 
solvent must be excluded from these regions, thus they are typically found clustered at the 
center of an interface. However, since most interfaces are flat, it would be difficult to 
achieve this sequestration without some method of screening solvent molecules at the 
perimeter of the interface. Studies have shown that the partially solvent exposed residues 
at the edges of an interface generally only make minor contributions to the free energy of 




solvent molecules from disrupting interactions at the center of the interface. This theory 
has come to be known as the O-ring theory. 
If the O-ring theory is true, then the residues found in hot spots should be 
significantly hydrophobic or capable of engaging in hydrogen bonding or salt bridge 
formation. The strength of these associations are enhanced by the decreased dielectric 
which results from solvent exclusion.20 Analysis of the amino acid composition of hot spots 
has shown that they are highly enriched in tryptophan (trp), arginine (arg), and tyrosine 
(tyr) while also being deficient in leucine (leu), methionine (met), serine (ser), threonine 
(thr), and valine (val).14,15 It has been posited that the reasons for these propensities are 
related to the ability of the amino acid side chains to engage in various types of stabilizing 
interactions as well as the entropic penalty paid for immobilization of the side chains at an 
interface. 
The three most common amino acids found at hot spots (trp, arg, tyr) are all capable 
of engaging in hydrogen bonding and hydrophobic interactions (the arg side chain contains 
three methylene groups). The two aromatic side chains are also able to engage in π stacking 
interactions. Arg can interact with the aromatic side chains via cation – π interactions, in 
addition to the five hydrogen bonds that it is capable of forming. The least abundant amino 
acids can primarily only engage in a single type of interaction via their side chain, either 
hydrophobic associations (leu, met, val) or hydrogen bonding (ser, thr). Further, 
immobilization of these side chains at the interface surface is likely to be highly 
entropically unfavorable. Being more rigid due to their aromaticity, the trp and tyr side 
chains are likely to be less disfavored. In addition, the extensive interactions available to 




entropic penalties of their immobilization. Interestingly, viral capsids have been shown to 
have fewer aromatic residues at their interfaces while having more uncharged polar 
residues.21 This lack of aromatic residues and enrichment in polar ones may be due to the 
metastable nature of such capsids which requires them to be stable enough to withstand 
environmental challenges but not so strong that they cannot dissociate within their target 
cells. 
1.1.3 Driving Forces Behind Interface Association 
Protein-protein interactions are dominated by noncovalent associations such as 
hydrophobic interactions, hydrogen bonding, and salt bridge formation.22 In particular, the 
burial of hydrophobic surface area is usually a major contributor to interface stability. This 
contribution is entropically driven due to the release of the ordered layer of water which 
surrounds the hydrophobic surface when it is solvent exposed. Van der waals contacts 
between hydrophobic residues of the adjacent subunits help to further stabilize the 
interaction and promote tighter packing of the interface. The degree of buried hydrophobic 
surface area can vary significantly, particularly between transient and obligate interfaces, 
but seems to reach an average of approximately 60%.17,18 This average does not correlate 
with the size of the interface. It has been speculated that this average is an evolutionary 
constraint which prevents nonspecific aggregation of proteins. In addition to hydrophobic 
associations, polar interactions also play a significant role in the strength, stability, and 
specificity of protein-protein interfaces.  
Hydrogen bonds are found in both polar and nonpolar regions of proteins due to the 




average of 76% of hydrogen bonds at an interface are between side chains. Individually, 
they are fairly weak bonds but what they lack in strength they make up for in numbers. The 
total number of hydrogen bonds is significantly associated with the interface’s buried 
accessible surface area with an average of 1 hydrogen bond per 200 Å2.22,23 This ratio 
increases to 1 bond per 75 Å2 when only polar area is considered.17 It has been estimated 
that as few as 10 hydrogen bonds in a buried surface of 1500 Å2 could result in a picomolar 
range KD for the interaction.
24 Both inter- and intramolecular hydrogen bonds have been 
found to increase the strength and stability of protein-protein interactions. This 
enhancement is thought to be due to an increase in the enthalpy of binding that helps offset 
the entropic penalty resulting from immobilization of the interface. 
Salt bridges are another polar interaction commonly associated with interface 
stability and specificity.25 A significant pairing preference between oppositely charged side 
chains has been detected for residues at both homooligomeric and heterooligomeric 
interfaces.26 An average of two salt bridges per interface has been estimated although the 
actual number observed can vary significantly.25 A weak direct correlation between 
interface size and the number of salt bridge networks has been detected in some data sets. 
Despite their polar nature, salt bridges are often buried at protein-protein interfaces. This 
burial has likely evolved as a way to both strengthen the interaction by lowering the 
neighboring dielectric and prevent disruption of the salt bridge due to solvation of the 
interacting side chains. 
These forces, hydrophobic and polar interactions, work together to maintain 
protein-protein interfaces. The specific nature of the association will dictate which of these 




associations tend to rely more upon polar interactions while obligate interfaces, which are 
more permanent in nature, typically better resemble a protein core with a significant degree 
of buried hydrophobic residues.27,28 Regardless of the duration of the association, hydrogen 
bonding, salt bridge formation, and topological complementarity have been found to play 
a key role in the specificity of the interface. 
1.2 Protein Capsids 
1.2.1 Icosahedral Capsid Architecture 
A capsid is a hollow, regular structure formed by multiple self-assembling protein 
subunits. Capsid assembly proceeds via a complex and systematic pathway in which 
monomers assemble into higher order oligomers that then come together to create the 
closed capsid. This process is highly concentration dependent and exhibits sigmoidal 
association kinetics in which assembly is slow until a critical concentration of building 
blocks is reached.29, 192 At this point, production of whole capsids proceeds very quickly 
and finishes with few or no intermediate assembly states left over. These results strongly 
indicate that capsid assembly begins with a nucleation site, sometimes facilitated by 
binding of the monomers to scaffold proteins or, in the case of viruses, genomic material. 
The most frequently encountered form of the protein capsid is an icosahedron. These 
polygons account for the structure of approximately half of all viral capsids as well as a 
significant number of bacterial capsids.  
The geometry of an icosahedron is that of an approximately spherical, enclosed 
structure with 20 triangular facets and 12 vertices on its exterior surface. Each facet may 




perfect symmetry would require that icosahedral capsids assembled from homologous 
subunits must be built from 60 of them.21 However, many icosahedral capsids are known 
to exist which are comprised of significantly more subunits. This observation gave rise to 
the theory of quasi-equivalence which states that increments of 60 identical subunits may 
be tiled across an icosahedral surface by arranging them into 12 pentamers and varying 
amounts of hexamers.30 The number of hexamers increases with the number of subunits. 
Although not identical, the contacts made by subunits within the pentamers and hexamers 
are very similar, hence the term quasi-equivalence. The resulting structures can be 
described by their icosahedral triangulation number. 
The triangulation number (T) is calculated from the following equation: 
T = h2 + hk + k2     (Equation 1.1) 
where h and k are positive integers corresponding to the number of steps along each axis 
of a two-dimensional plane required to move from one pentamer across the intervening 
hexamers to the next nearest pentamer. The total number of monomers in a capsid will be 
equal to 60T while the total number of hexamers is equal to 10(T-1). Since an icosahedron 
possesses 12 vertices and the pentamers are present only at the vertices, there are always 
exactly 12 pentamers in an icosahedral capsid. Heterooligomer capsids which obey the 
geometric constraints of an icosahedron despite having different monomer subunits are 
described with a pseudo-T number, abbreviated as P. 
1.2.2 Viral Capsids 
The most common examples of protein capsids found in Nature are viral capsids. 




as it is transported between host cells. Additionally, capsid proteins often play key roles in 
loading of the genome, specific cell targeting, and unloading of the capsid contents into the 
host cell. Thus proper assembly of the capsid is crucial to the viral lifecycle. These 
assemblies are usually highly symmetric with icosahedral capsids being among the most 
commonly found shapes. 
The icosahedral viral capsids vary in size from 17 – 400 nm primarily depending 
upon the size of the genome they must encapsulate.31,32 The necessity of loading 
nucleotides has led virtually all of these capsids to have some degree of positive charge on 
their interior surface. In the case of RNA viruses, the capsid proteins often possess an 
N-terminal arginine rich motif that greatly enhances binding of nucleic acids.33 Viruses 
have also evolved a functionalized exterior surface which often displays receptor binding 
proteins used to gain entry to highly specific target cells. The potential to exploit this built-
in multivalent display system or to load the capsid with a variety of guest molecules makes 
viral capsids attractive protein engineering scaffolds. Among the most widely used viruses 
for nanotechnology applications are the cowpea chlorotic mottle virus (CCM)34 and 
bacteriophages MS2,35 Qß,36 and P2237. 
CCMV is a plant virus which forms a 180 subunit T = 3 icosahedral capsid of 
approximately 30 nm diameter. It has been widely studied for use in nanotechnology 
applications due to its good overall stability and its inherent, reversible pH assembly 
switch. The capsid disassembles into 90 dimers at a pH of 7 and can be made to reform by 
lowering the pH to 5 (see section 1.3.1).38 
Both of the bacteriophages MS2 and Qß form 180 subunit T = 3 icosahedral capsids 




of approximately 30 nm. Both have been shown to be thermostable and tolerant of 
mutations, making them good candidates for engineering.  
The bacteriophage P22 capsid is composed of 420 monomers arranged as a T = 7 
icosahedral capsid. This 58 nm capsid is referred to as the procapsid (PC). It undergoes 
expansion to the 64 nm mature capsid (EX) in response to DNA loading or heating at 65 °C 
for 10 minutes. Continued heating at 75 °C for at least 20 minutes causes the EX capsid to 
specifically dissociate the pentamers located at each vertex, thereby opening 10 nm pores 
and adopting the wiffleball (WB) form. This virus was initially selected for development 
as a nanotechnology scaffold due to its fairly large size and therefore high potential loading 
capacity. 
1.2.3 Bacterial Microcompartments 
Among the largest nonviral capsids are the bacterial microcompartments (BMC). 
These organelles are typically 80 – 200 nm in diameter and are assembled from families of 
BMC-domain bearing proteins.39 These shell proteins form homohexamers which then 
associate in two-dimensional layers. Homopentamers lacking BMC-domains sit at the 
vertices of a rough icosahedral capsid and serve to direct the folding of the homohexamer 
sheets to form the faces of this capsid. These complex capsids have been found to contain 
as many as 8 different shell proteins. BMCs encapsulate several different enzymes in 
pathways whose intermediates are capable of easily diffusing out of the cell and/or are 
toxic in the cytoplasm. The archetypal BMC is the carboxysome. 
The enzymes encapsulated within the carboxysome, ribulose-1,5-bisphosphate 




the carbon fixation pathway. CA converts bicarbonate (HCO3
-) to CO2 which RuBisCO 
then adds to ribulose-1,5-bisphosphate (RuBP) to form two molecules of 3-
phosphoglycerate. RuBisCO is an inefficient enzyme40,41 and if it is not co-encapsulated 
with CA, the CO2 produced by the latter diffuses out of the cell before RuBisCO can bind 
it42,43. Further, RuBisCO is competitively inhibited by O2. The carboxysome shell is 
permeable to HCO3
- but not CO2 or O2. Thus, substrate is retained and concentrated to help 
offset RuBisCO’s inherent inefficiency while also preventing exposure to an otherwise 
ubiquitous inhibitor.  
The natural existence of BMCs serves as an excellent proof of concept that 
encapsulation of enzymes within a protein shell can lead to enhancements in individual 
enzyme activity or flux through the pathway as a whole. Most examples of engineered 
protein nanoreactors have exhibited mild decreases in overall catalytic efficiency although 
small improvements have been seen in some individual parameters. While BMCs are 
currently far more complex than the engineered nanoreactors produced to date, they 
demonstrate what may one day be accomplished when we have a much more advanced 
understanding of the intricate nature of protein-based supramolecular assemblies. 
1.2.4 Catalytic Bacterial Capsids 
Protein capsids often serve to group together several different enzymes in a 
pathway either through encapsulation or by acting as a scaffold. In addition to structural 
and container functions, capsids can possess catalytic activity of their own. They have been 
found to play significant roles in reactions related to detoxification, storage, immune 




Ferritin is a 24 subunit octahedral protein capsid found in all forms of life. In 
bacteria, it exists as a homooligomer while in higher order organisms, it can often be found 
as a heterooligomer composed of two separate chains.44 It plays a critical role in iron 
metabolism where it serves to detoxify excess iron by converting Fe2+ to Fe2O3. This 
mineral is then stored in the capsid interior and released when iron levels are low. 
Sequestration of iron via this method has also been implicated to play a role in host immune 
response to bacterial pathogens.45 Thus, this capsid employs catalysis of iron 
mineralization to maintain iron homeostasis and protect the cell from damaging free 
radicals and foreign organisms. 
The pyruvate dehydrogenase complex (PDC) is composed of three separate 
enzymes which, together, catalyze the decarboxylation of pyruvate to form acetyl-CoA. 
This conversion links glycolysis and the citric acid cycle. The second enzyme in this series, 
dihydrolipoamide acetyltransferase (E2), forms a 24 subunit octahedral capsid in 
prokaryotes and Gram – negative bacteria46 or a 60 subunit T = 1 dodecahedral capsid in 
eukaryotes and Gram – positive bacteria.47 The first (pyruvate dehydrogenase, E1) and 
third (dihydrolipoamide dehydrogenase, E3) enzymes in the reaction cascade bind to the 
exterior surface of both capsid forms. The prokaryotic E2 capsid binds E1 and E3 via a 
peripheral subunit binding domain (PSBD) which is part of the E2 structure. The 
eukaryotic E2 capsid also employs a PSBD to bind E1 but uses a catalytically inert E3 
binding protein to attach E3 to the capsid’s outer surface. Thus, both forms of the PDC rely 
upon a capsid core to produce supramolecular complexes which enhance the overall flux 
through the reaction pathway. 




(BsRS) catalyze the penultimate and last steps in riboflavin synthesis, respectively.48 Like 
E2 of the PDC, BsLS also forms a 60 subunit icosahedral capsid.49 However, rather than 
decorating the outer surface, it encapsulates a trimeric form of BsRS, presumably through 
the use of an as yet unidentified recognition domain similar to the E2 PSBD. It is interesting 
that both the PDC and BsLS/BsRS complexes have evolved icosahedral capsids as part of 
their supramolecular assemblies but then functionalized different surfaces of the capsid. 
This difference is likely due to the unique evolutionary requirements imposed on each 
structure.  
The BsLS active site is located on the interior surface of the capsid. This design 
allows for the accumulation of BsRS and its substrate in the capsid lumen. BsRS needs to 
function under conditions of low substrate concentration and is not subject to regulation by 
other enzymes. A high local concentration of substrate could allow the enzyme to function 
at overall substrate concentrations that would otherwise be too low for efficient catalysis 
to take place.50 The rate of flux through the pathway also likely benefits from the 
colocalization of the enzymes catalyzing the last two steps via substrate shuttling from the 
BsLS active site to that of BsRS. 
On the other hand, PDC activity is very tightly regulated by two enzymes which 
control phosphorylation of the E1 subunit.51 These enzymes are bound to the complex via 
a lipoyl domain on the E2 subunit. Encapsulation of E1 would then require that these 
regulatory enzymes also be encapsulated. There may not be sufficient room within the 
capsid to allow for encapsulation of all of these proteins or, more likely, it was just simpler 
and more efficient to evolve external colocalization. Regardless of exactly why they 




examples of the ways in which the various surfaces of protein capsids may be 
functionalized to enhance and control enzymatic activity. 
1.3 Capsid Functionalization 
1.3.1 Cargo Loading 
One of the most common ways in which proteins produce supramolecular 
assemblies is via recognition domains encoded in the protein’s primary structure.52–55 
These domains fold into specific secondary and tertiary structural elements which strongly 
associate with a complementary domain in the other binding partner. In some instances, 
binding occurs between a prosthetic group on one of the proteins and a binding site on the 
other protein. For example, the E1 kinase and dephosphorylase regulatory enzymes of the 
PDC bind to the lipoyl moieties on the E2 subunit. Capsids which naturally contain other 
proteins typically achieve encapsulation by using this recognition domain strategy.  
Viruses often employ this strategy to bind their coat proteins to the scaffolding 
proteins which help the capsid assemble.56,57 For example, of the 303 amino acids which 
comprise the P22 scaffold protein, only 15 near the C-terminus mediate binding to its 
capsid coat proteins during the initial nucleation and assembly stages.  
Bacteria have also evolved capsids that employ this method of cargo loading. 
Encapsulins are T = 1 capsids which have been found to play a role in oxidative stress 
response by encapsulating a peroxidase and a ferritin-like protein. Loading of these 
enzymes is achieved via a 30 - 40 residue recognition domain located at their C-termini.58 
Unsurprisingly, higher order organisms have also evolved nanocontainers which function 




Vaults are large, eukaryotic organelles whose function is not completely 
understood although they appear to be involved in pathogen defense. They have been found 
to encapsulate proteins expressing a 161 residue recognition domain, again, at the 
C-terminus.59 Numerous studies have demonstrated that genetic fusion of these and other 
recognition domains to various proteins results in the efficient encapsulation of the chimera 
by the capsid specific to each recognition domain.  
Similarly, an RNA aptamer-based approach was developed in which the Qß capsid 
protein mRNA was modified to encode a peptide binding sequence at one end and a 
packaging hairpin at the other.60 Co-expression of the capsid proteins with enzymes fused 
to the targeting peptide resulted in encapsulation of those enzymes via association with the 
viral mRNA. Another, RNA-derived system employed MS2 mRNA covalently linked to a 
guest molecule to achieve capsid loading.61  
Finally, two other encapsulation systems have been developed, both of which rely 
on charge complementarity. One is a derivative of the MS2 system described previously 
which takes advantage of the viral capsid's inherent positive charge to encapsulate guest 
molecules.62 The other system uses an engineered bacterial capsid with a negatively 
charged interior surface (see section 1.5.2 for further information).63 Both systems require 
tagging of the intended guest molecule with a short peptide ranging from 10 to 16 residues 
in length whose side chains possess a net charge opposite that of the interior of the intended 
container. These electrostatic encapsulation systems are less specific than the 
aforementioned recognition domain derived methods but they employ significantly smaller 




Any capsid with a native net charge on its lumenal surface or capable of being 
engineered to possess such a charge should be able to encapsulate guests tagged with a 
complementarily charged peptide. As an alternative to tagging a guest molecule, 
supercharging of its surface has also been shown to produce efficient encapsulation.64,65 
However, supercharging is much more difficult to accomplish without disrupting the 
structure and function of the guest. 
Finally, not all potential guest molecules are large. The ability to load capsids with 
small molecules is crucial to a number of their engineered functions, particularly as 
delivery vehicles. This loading is often achieved by covalently tethering the small molecule 
guests to specific residues on the interior surface of the capsid.66,67 However, loading 
capacity is then limited by the number of available residues and the efficiency of the 
tethering reaction. Recent work with the heat shock protein G41C, Qß, and P22 capsids 
has shown that constrained growth of a polymer within the capsid lumen can greatly 
enhance loading of small molecules by providing a larger internal surface area and 
significantly more binding sites.68–70 
While these methods have been very successful at achieving encapsulation, they do 
not provide an effective means of freeing the cargo molecules from the capsid, such as 
would be desired in a drug delivery vehicle or a nanoreactor whose products are too large 
to exit the capsid via its pores. Efforts to solve this problem have largely centered around 
developing capsid variants whose building blocks dissociate or assemble based on the 





1.3.2 Capsid Assembly Switches 
It has been shown that viral particles obtained by disassembling fully formed 
capsids can be induced to reassemble into capsids in the presence of a negatively charged 
polymer.71 Presumably, this functions by mimicking the encapsulation of the virus' 
genomic material. However, these methods only provide control over assembly and reduce 
the available space for capsid loading. Nature has already done much of the heavy lifting 
to develop assembly switches in viral capsids. Owing to the need for virus' to deliver their 
genome into host cells, they are metastable supramolecular assemblies which can be 
disassembled by exposure to various environments within the cell. This disassembly is 
typically irreversible due to the release of encapsulated genetic material. However, several 
viral capsids have been found to disassemble and reassemble without their genomes in vitro 
via exposure to environmental conditions other than those usually seen in vivo. Few 
bacterial capsids have been found to possess inherent assembly switches, possibly due to 
the lack of an evolutionary need to disassemble. 
1.3.2.1 Naturally Occurring Assembly Switches 
The CCMV capsid is perhaps the best studied example of a reversible capsid 
assembly switch. It can be made to dissociate into dimers by raising the pH above 7 while 
simultaneously raising the ionic strength of the solution above 1 M.38 These dimers can 
then be induced to reassemble by lowering the pH to approximately 5. Reassembly occurs 
at this pH for both high and low ionic strengths but at lower levels, capsid assembly is less 
efficient. The presence of DTT also decreases the reassembly efficiency, resulting in some 




The only reports of naturally occurring, reversible pH switches in bacterial capsids 
were observed in several DNA-binding proteins from starved cells (Dps)72 and horse spleen 
apoferritin.73 The Dps family of proteins possess ferroxidase activity and are members of 
the ferritin superfamily. They assemble into distorted icosahedral capsids which reversibly 
dissociate into dimers below pH 6.0 or above pH 7.5. This disassembly has been attributed 
to the disruption of salt bridges formed at the three-fold and two-fold interfaces. 
Apoferritin is ferritin which does not possess bound iron atoms. Rather than 
assembling as an octahedral capsid, apoferritin is spherical. It was shown that this capsid 
partially dissociates to various degrees as the pH drops below 3 and that the spherical 
capsid can be reconstructed from some of these dissociation products, albeit with minor 
defects, upon return to physiological pH. Disassembly switches are far more common than 
reversible switches, particularly in viral capsids.  
The T = 1 icosahedral foot and mouth disease virion (FMDV) capsid was found to 
dissociate around pH 5.74 This disassembly is believed to be due to charge repulsion 
between a histidine residue upon protonation at lower pH and an α-helix dipole present at 
the two-fold pentamer-pentamer symmetry axis. In support of this hypothesis, mutation of 
the histidine to arginine destabilizes the capsid while mutation to aspartate resulted in 
improved acid stability. Another virus, hepatitis B (hepB), has been shown to possess two 
different disassembly switches. 
A truncated form of the hepB capsid protein which is missing the last 34 amino 
acids of the C-terminus has been shown to assemble normally into a 240 subunit T = 4 
capsid like the full length protein.75 This capsid may be dissociated into dimers under 




reassembled by either lowering the pH to 7 in 250 mM ionic strength buffer or by 
increasing the ionic strength to 250 - 500 mM at pH 9.5. The presence of DTT significantly 
slows the reassembly process and decreases the total amount of capsid reformed. Despite 
the lower yield, slowing the reassembly process could result in higher loading of the capsid 
by guest molecules and merits further study. 
The polyomavirus family possesses two members who display unique assembly 
switches in addition to the pH and ionic strength switches described above. These viruses 
form 360 subunit T = 7 capsids from 72 pentamers of a single protein (VP1) with the 
assistance of two other proteins (VP2, VP3) which interact with the interior of the capsid. 
VP1 alone is capable of assembling into capsids and other structures depending on the 
solution conditions.  
Like hepB, the murine polyomavirus (MPV) and simian virus 40 (SV40) have been 
shown to possess an assembly switch in which capsid assembly can be induced via high 
ionic strength ( > 1 M) or low pH (6.0 – 6.4).76–78 MPV assembles into T = 1 icosahedral 
capsids under both conditions. SV40 also assembles into T = 1 capsids at high ionic 
strength but adopts a long tubular form at low pH. With SV40, these structures can also be 
produced by titrating VP1 pentamers with VP2 under various solution conditions.79  
Metal induced assembly of MPV or SV40 can be achieved through the addition of 
100 – 200 µM Ca2+ to the buffer solution at pH 7.2. Treatment with other divalent metal 
cations showed no assembly induction.77,78 Further, this metal induced assembly was fully 
reversible by treatment with the calcium chelator EGTA under reducing conditions. 
Subsequent removal of the reducing agent and addition of calcium causes MPV to reform 




1.3.2.2 Engineered Assembly Switches 
Metal inducible capsid assembly has been successfully engineered into two 
separate protein capsids. Ferritin was modified by the mutation of four amino acids to 
histidines at its two-fold symmetry interface to produce two copper binding sites. Three 
more mutations were then introduced to the same interface in order to destabilize it 
sufficiently that the capsid did not assemble unless Cu2+ was present.80 This switch was not 
reversible as removal of the copper ions via treatment with EDTA did not cause the capsid 
to disassemble.  
The other capsid successfully engineered to possess a metal assembly switch was 
CCMV.81 This switch was created by appending a six histidine tag to the N-terminus of the 
CCMV monomer which is located at the five-fold and quasi six-fold symmetry axis'. 
Addition of nickel to the capsid at pH 5 allowed it to remain assembled at pH 7.5 where 
the wild type capsid dissociates into dimers. Treatment of the mutant capsid with EDTA at 
this pH caused the capsid to disassemble, indicating that this switch is bidirectional. 
CCMV is also the only capsid so far for which a thermal assembly switch has been 
developed.82 This switch was developed by genetically replacing the first 26 amino acids 
of the CCMV monomer with a hexahistidine tag (for easy purification) and a series of nine 
elastin-like polypeptide (ELP) repeats. ELP polymers have been shown to contract in 
response to heating.83 Assembly of the CCMV-ELP mutant via the native CCMV pH 
switch or by heating briefly in high ionic strength buffer resulted in the formation of an 
ELP shell inside the CCMV capsid. Assembly by pH manipulation resulted in the standard 





To date, two bacterial capsids have been engineered with pH switches. The Bacillus 
stearothermophilus PDC E2 subunit forms a T = 1 capsid in which the N-terminal arm 
stabilizes neighboring subunits. Removal of the first 50 amino acids of the N-terminus 
sufficiently reduced the overall capsid stability such that protonation of naturally occurring 
histidines at the three-fold symmetry axis caused dissociation of the truncated capsid 
between pH 6 – 6.5 at low ionic strength and pH 7 – 7.5 at high ionic strength.84 This 
disassembly was not shown to be reversible. 
The other capsid to receive an engineered pH switch, formed by Aquifex aeolicus 
lumazine synthase, is discussed in detail in section 1.5.2. Briefly, mutations which disrupt 
an ionic network at the two-fold symmetry axis and introduce a set of three histidines at 
the three-fold axis allowed for disassembly of the capsid by lowering the pH from 8 to 5.7 
and subsequent reassembly by raising the pH in the presence of PEG-3350.85 
Examination of the various natural and engineered assembly switches reveals 
significant utility for histidines as key features in both pH and metal induced assembly 
switches. This functionality is due to the moderate pKa of its imidazole moiety and the fact 
that this group is capable of chelating several different metal ions. Its side chain pKa of 
approximately 6.0 allows for modulation of the residue's charge state at physiologically 
relevant pH ranges. These facts suggest that histidine containing sequences may be useful 






1.3.3 Functionalization of the Capsid Exterior 
The exterior surface of protein capsids have been extensively modified in nature. 
Given the symmetric character of most capsids, this modification often leads to the 
uniform, multivalent display of proteins and prosthetic groups. The primary benefit of such 
display is enhancement of binding to targets through avidity effects. Just as having many 
weak interactions at an individual binding site may lead to a very strong overall interaction, 
association of many identical binding sites between complexes greatly increases the 
effective affinity, or avidity, of these associations as a whole. 
For example, many viruses display receptor binding proteins on the outside of the 
capsid as a way of targeting and entering specific cells. Studies have shown that increasing 
the number of receptor binding proteins on the capsid surface results in more efficient 
uptake of the virus by the cell.86 Similarly, DNA viruses also use the outer capsid surface 
to gain entry to the cell nucleus.87 Proteins recruited to the exterior of the viral capsid have 
been found to play critical roles in the formation of viral envelopes via lipid recruitment or 
in the induction of apoptosis in host cells.88,89 In at least one case, a virus has evolved a 
triple layer of concentric capsid shells for which the inner layers presumably recruit the 
outer layers.90 
Bacterial capsids also exhibit functionalization of their outer surface. Since these 
capsids do not need to exit the cell, their modifications usually address the capsid to various 
regions of the cell interior or promote supramolecular assembly around the capsid.91,92 





Inspired by nature, researchers have developed a variety of different methods of 
enhancing capsid utility via modification of the exterior surface. Covalent modification of 
different amino acid side chains has been demonstrated to allow for the uniform, 
multivalent display of proteins as well as several different prosthetic groups including 
biotin, chromophores, haptens, and PEG.93,94 
In particular, PEG modification of the capsid surface shows significant promise in 
enhancing the ability to use protein capsids in industrial processes by improving the 
solubility of the capsid in various organic solvents while simultaneously imparting greater 
thermal stability.93 It is also an effective method of preventing antibody recognition of the 
capsid which is a major problem associated with the use of viral capsids as drug delivery 
vectors.95–98 The unbound end of the PEG chain may also be modified to serve as a binding 
site for further additions to the capsid exterior. 
In some cases, permanent attachment of the guest to the capsid exterior may not be 
desirable. The use of genetic modifications such as hexahistidine tags and coiled – coil 
motifs allows for dissociable interactions between the capsid and a guest molecule.99,100 
These tags have been appended to the solvent exposed N- or C-terminus of different 
capsids to allow for the binding of heme groups or gold nanoparticles and should be broadly 
applicable to other binding interactions. This approach was also used to create a 
multilayered immobilized network of bound capsids. While this technique is a versatile 
and fairly straight-forward method of producing protein interaction sites, it is incompatible 
with capsids whose termini are not exposed at the surface to be modified or those which 
make extensive subunit contacts as these are typically important stabilizing associations. 




seen some success, but this route carries a significant risk of destabilizing the capsid.101 A 
method of noncovalently decorating the outer surface of the capsid without introducing 
any genetic modifications has been developed. 
In a similar approach to that which has had much success in encapsulating guest 
molecules, a whole protein or domain capable of binding to the exterior surface of the 
capsid is fused to a guest molecule.102 This fusion allows for display of the guest on the 
outside of the capsid without the need to alter the capsid itself. Many of these capsid 
binding proteins exist for several different capsids. Alternatively, the combination of this 
method with one or more of the previously described methods of decorating the capsid 
exterior could allow for the simultaneous multivalent display of several different guest 
molecules on the capsid surface. 
Lastly, the work presented in Chapter 3 demonstrates a novel means of decorating 
the outer surface of a capsid by functionalizing the pores at the five-fold symmetry axis. 
Charge complementarity was employed as a means of binding a tagged guest molecule 
with the tag presumably threading through the pore.  
1.4 Nanotechnology Applications of Protein Capsids 
1.4.1 Medical Uses for Capsids 
A significant problem associated with many medical treatments, particularly cancer 
treatments, is efficient delivery of the therapeutic or diagnostic agent to target tissues. 
Many current treatments are nonspecific and rely on large doses to achieve delivery of 
functional drug levels to the intended sites of action. This shotgun approach often harms 




than a well targeted delivery, which exacerbates the side effects and raises the cost of 
treatment.  
Protein capsids have shown great promise for use as highly addressable drug and 
bio-imaging delivery vectors.103–107 Loading of small molecules is often accomplished via 
covalant conjugation to specific amino acids on the interior surface of the capsid while 
attachment of cell specific receptors to the exterior results in highly efficient uptake in the 
target tissues. In general, encapsulation by a variety of molecules, including lipids and 
proteins, has been shown to reduce toxicity and enhance uptake of various drugs.108–110  
In addition, sequestration of drug or bio-imaging compounds inside capsids has 
been shown to extend the half-life of these molecules in vivo to days or even as long as 
several months.111 This longer half-life opens up the possibility of engineering slow release 
treatments which allow for sustained dosing or long-term metabolic studies without the 
need for multiple injections.  
Capsids have also been used to create improved vaccines by enhancing their 
stability or through multivalent display of antigens on the exterior capsid surface.112–114 
Avidity effects improve binding of humoral and cellular immune components to the 
antigen which results in strong activation of B cells and T lymphocytes, ultimately 
producing high levels of specific antibodies. Viral capsid-based vaccines are currently 
showing significant success as a means of activating the immune system against HIV and 





1.4.2 Materials Synthesis 
Production of monodisperse nanoparticles and polymers is a challenge that protein 
capsids have been used to address. Their uniform size and hollow interiors make capsids 
ideal as templates or nucleation sites for controlled biomineralization. Several different 
capsids, including CCMV and Qß, have been used as reaction vessels to control a variety 
of mineralization reactions.117–119 However, owing to their inherent activities as 
ferroxidases and iron storage sites, ferritins have been the most extensively developed for 
this function. 
The ferritin family of proteins are generally able to bind a wide variety of metals. 
This property has been exploited to produce several different metal nanoparticles, 
bio-imaging contrast agents, semiconductors and metal catalysts.120 Ferritin's metal 
binding capabilities have also led to it being investigated as a component in biofuel cells 
as an electron transfer mediator.  
In this capacity, ferritin picks up electrons from the enzyme diaphorase and 
transfers them to a polypyrrole polymer which then delivers the electrons to the fuel cell 
anode. Incorporation of ferritin as part of this reaction cascade resulted in an enhanced 
electron transfer efficiency which demonstrated its potential for use in future biofuel cell 
designs.121 
As mentioned at the end of section 1.3.1, capsids have also been used to regulate 
the size of several different polymerization reaction products. Although, to date, these 
reactions have only been used to enhance small molecule loading of the capsids, it is 
possible that this method of polymer growth inside a nanocontainer could be used to 





The use of enzymes to replace expensive inorganic catalysts and harsh reaction 
conditions in industrial processes is highly desirable and has been the subject of intense 
research efforts. However, naked enzymes suffer from a number of problems which have 
impeded their wide-scale industrial use, including relatively short half-lives, thermal 
instability, intolerance to organic solvents, and poor scale-up efficiency. It has been 
demonstrated that protein capsids may be modified to withstand these inactivating 
conditions, thus encapsulation has the potential to confer these advantages to the guest 
enzymes. In addition, the observation that there exist naturally occurring nanoreactors 
which exhibit enhanced activity in comparison to the free enzymes has led to the 
speculation that encapsulation could improve reaction kinetics and thereby address the 
scale-up efficiency problem as well. Although promising, the science of nanoreactors is 
still very much in its infancy. 
The majority of early capsid engineering work focused on drug delivery 
applications. The first engineered protein nanoreactor was reported in 2007. It was 
demonstrated that CCMV could be used to encapsulate an active horseradish peroxidase 
and that substrate molecules could diffuse into the capsid interior.122 Less than six months 
later, SV40 was used to encapsulate cytosine deaminase and deliver it, in active form, to 
CV-1 cells.123 Although this construct fits the definition of a nanoreactor, the focus of the 
experiments were still on drug delivery applications.  
No further nanoreactor systems were reported until late 2010 when the Qß capsid 
was used to encapsulate two different enzymes with the specific goal of examining the 




been an average of two new nanoreactors reported per year with the majority being 
developed by the Douglas lab using the P22 capsid62,124–130. Although all of these recent 
studies have examined the encapsulated enzyme kinetics of their respective nanoreactors, 
the exact factors which influence these kinetics is still not well understood.  
For a detailed discussion of encapsulated enzyme kinetics, please see section 2.3. 
Briefly, enzyme encapsulation seems to have either no significant effect upon the 
confinement kcat (kcat, conf) or decreases it by less than an order of magnitude. The 
confinement Km (Km, conf) is also typically unchanged or slightly decreased, leading to an 
overall confinement turnover number (kcat, conf/Km, conf) that is roughly an order of 
magnitude lower than that of the free enzyme. However, three of the reported nanoreactors 
exhibited significantly increased Km, conf values. Our own nanoreactor, as reported in 
Chapter 2, also exhibited aberrant behavior with the single largest decrease in kcat, conf of 
any reported system to date. These outliers demonstrate that, while significant progress has 
been made in the study of nanoreactors, there are still vast swathes of uncharted territory 
to explore in this field. 
1.5 Aquifex aeolicus Lumazine Synthase as a Protein Engineering Scaffold 
1.5.1 The AaLS Capsid 
Aquifex aeolicus lumazine synthase (AaLS) is a 60 subunit T = 1 icosahedral 
capsid. The individual monomers are 154 amino acids long with a molecular weight of 
16.7 kDa, yielding a capsid with a molecular weight of approximately 1 MDa. The capsid 
is best viewed as a dodecamer of pentamers due to the extensive monomer-monomer 




nm in diameter with a shell thickness of around 3.5 nm, giving an internal diameter of 
roughly 9 nm. The shell is solid with the exception of moderately sized pores at each of its 
five-fold symmetry axes.131 
AaLS catalyzes the penultimate step in riboflavin synthesis and the five-fold axial 
pores are likely portals for entry of substrate into and egress of products from the interior 
of the capsid, where the active sites are located. The pores are formed by the third -helix 
of each monomer of the pentamer (residues 90-108). These helices possess five turns, are 
27 Å long, and give the pore an hourglass shape with the narrowest point located 
approximately halfway through the pore at lysine 98 (Fig 1.1b). At this point, the pore is 
only 13.7 Å across, as measured between Catoms in the backbones of parallel residues. 
Previous work on a pentameric lumazine synthase from Saccharomyces cerevisiae (ScLS) 
has demonstrated that mutation of the solvent exposed residues lining the pore does not 
necessarily disrupt the association of the pentamer.132 Due to the high sequence homology 
between ScLS and AaLS, the AaLS pores were expected to be equally robust. 
Indeed, since A. aeolicus is a hyperthermophile, the entire AaLS capsid is extremely 
stable with a melting temperature of 120 °C. It possesses a buried surface area of 555,145 
Å2, of which 53.3% is hydrophobic. Such extensive sequestration of hydrophobic surface 
is a hallmark of highly stable protein – protein interfaces. Further, the total exterior surface 
area of the capsid is 276,102 Å2, of which 60.3% is charged. This significant degree of 
exposed surface charge is indicative of a high number of ion pairs and, unsurprisingly, 
AaLS was found to have more ion pairs (17) than any other icosahedral lumazine synthase. 
In particular, a six amino acid ionic network was found to stabilize the pentamer-pentamer 









Figure 1.1 The AaLS capsid. A) Surface representation of the AaLS capsid (right, PDB ID: 
1HQK). Pentameric (middle) and monomeric (left) building blocks are shown as ribbon 
diagrams extracted from the whole capsid structure. B) The five-fold axial pore viewed 
from the interior capsid surface. All labelled residues protrude into the lumen of the pore, 
except aspartate 108 which is located on the exterior surface of the pore. C) A volumetric 
representation of the pore lumen, viewed from the side, which demonstrates its slight 







the AaLS capsid to mutation makes it an ideal scaffold for use in a variety of protein 
engineering applications. 
1.5.2 Engineered AaLS Variants 
AaLS has been the subject of several studies designed to explore the potential of 
the capsid to be loaded with a variety of different guest molecules. The first of these studies 
introduced four mutations to the interior surface of the capsid (R83E, T86E, T120E, 
Q123E) designed to impart the lumenal surface with a significant negative charge. These 
mutations also caused the assembly state to shift from a 60 monomer T = 1 capsid to a 180 
monomer T = 3 capsid with a diameter of approximately 29 nm. This variant was named 
AaLS-neg.63 The mutant capsid was produced in order to demonstrate that appending a 
positively charged deca-arginine tag (R10) to a guest molecule (GFP, in this case) and co-
expressing both the capsid and the tagged guest in E. coli cells results in significant 
encapsulation of the tagged protein. 
Subsequent work involved expanding on the idea of a charge complementarity 
based encapsulation system. The R10 tag was appended to HIV protease which was then 
co-expressed with AaLS-neg133. This protease is toxic to the cell when free in the 
cytoplasm, thus its encapsulation provided a significant growth advantage over cells 
expressing the protease alone or co-expressed with the wild-type capsid. The researchers 
were able to use this growth advantage in a directed evolution experiment to select for 
capsids demonstrating an enhanced ability to encapsulate the tagged protease. The most 
effective of the variants that they found, termed AaLS-13, showed a 5- to 10-fold greater 




The AaLS-13 capsid possesses the following mutations, in addition to those found 
in AaLS-neg: D28G, R52C, T112S, V115D, A118D, R127C, and K131E. Only the latter 
two mutations alter residues which protrude into the lumen of the capsid. The other 
mutations occur at the various subunit interfaces. Overall, the mutations render each 
monomer significantly more negative which is likely the primary reason for the improved 
encapsulation efficiency observed with this capsid. EM imaging revealed a diameter of 
roughly 35 nm, indicating that the mutations also caused the capsid to expand to a 240 
monomer T = 4 structure.  
A follow-up experiment used positively supercharged GFP and AaLS-13 
pentamers, which are commonly separated from fully assembled capsids during 
purification, to demonstrate the ability to control in vitro loading by varying the ratio of 
pentamers to guest molecules.64 Interestingly, in vitro encapsulation could also be achieved 
using fully assembled capsids, suggesting the capsid is capable of at least partially 
disassembling to allow for guest loading. Further experimentation with a positively 
supercharged variant of ferritin resulted in encapsulation of between one and four ferritin 
capsids inside the AaLS-13 capsid, raising the possibility of creating a single nanoreactor 
with multiple internal reaction chambers.65 
The Woycechowsky lab then designed a variant called AaLS-pos which possessed 
mutations designed to impart the interior surface of the capsid with a net positive charge 
(T86R, D90N, T120R, and E122R).134 This capsid remained a 60 subunit T = 1 assembly 
like the wild-type. The purpose behind creating this mutant was to generate a nonviral 
protein capsid capable of binding cellular nucleic acids in vivo during protein production. 




of various sizes up to 350 bases in length, suggesting a maximum size limit for loading of 
the capsid. 
Finally, a method of halting capsid assembly at the pentamer stage and then 
introducing a redox switch to induce the pentamers to assemble into capsids was 
developed. It was found that disruption of the ionic network and hydrogen bonding sites at 
the two-fold symmetry axis (R40, H41) as well as a hydrophobic interaction site at the 
three-fold symmetry axis (I125) by introducing three mutations (R40E, H41E, and I125E) 
caused assembly to stop after the formation of pentamers.135  
Based on these results, a variant comprised of a similar set of mutations (C37A, 
R40S, H41S, I125C) was made (AaLS-switch-red). The C37A and I125C mutations were 
introduced to remove an endogenous cysteine and introduce one at the three-fold symmetry 
axis, respectively. The pentameric AaLS-switch-red was treated with DTNB to form an 
NTB adduct at cysteine 125, thereby priming the sidechain for a thiol disulfide exchange 
reaction in which thiophenol replaced the NTB moiety. After formation of the AaLS-
switch-thiophenol adduct (Switch-Ox), the modified pentamers were incubated with 10% 
PEG – 3350 for two days to induce capsid assembly.85 
To further expand upon the usefulness of the AaLS capsid, a pH assembly switch 
was designed by once again introducing mutations at the two-fold (R40S, H41S) and 
three-fold (T120H, E122H, Q123H) symmetry axes to produce the AaLS-switch-pH 
variant85. The histidines at the three-fold axis induce dissociation of the capsid via charge 
repulsion upon protonation of the histidine side chain. At pH 8 AaLS-switch-pH exists 
primarily as a capsid of comparable size and morphology to the wild-type AaLS capsid. 




a capsid peak can still be observed in the SEC chromatogram and lowering the pH further 
results in protein precipitation. Dialysis of the capsid into citrate buffer at pH 5.7 or 6.2 
yields only pentamers. Subsequent dialysis of these pentamers back into pH 8 phosphate 
buffer does not produce reassembled capsid. However, incubation of those pentamers with 
10 % PEG-3350 for four days results in an 86% yield of reformed capsid. 
AaLS is an extremely stable, highly manipulable protein scaffold. Its several 
engineered assembly switches and capsid variants possessing multiple different 
morphologies and charge states make it highly attractive for further development as a 
nanotechnology tool.  
1.6 Dissertation Aims 
The overarching goal of the work presented in this dissertation was to add to the 
body of knowledge regarding supramolecular assembly of protein molecules. AaLS was 
selected as a nonviral capsid scaffold due to its high stability and tolerance to mutations. 
The novel complexes described in the following chapters demonstrate the versatility and 
potential of protein capsids for nanotechnology applications. 
Chapter 2 discusses the effects of encapsulation on enzyme kinetics. A previously 
engineered AaLS capsid variant was used to encapsulate an esterase in vivo using a charge 
complementarity-based tagging system. The various factors at play when encapsulating 
enzymes and the effects they have on reaction kinetics are not well understood. Here I 
report an unusual finding which I speculate may be a result of the electrostatic environment 
within the capsid, a potential influence which has been previously unconsidered when 




In Chapter 3, charge complementarity is once again employed, only this time it is 
used to decorate the outer surface of the capsid. Many capsids possess pores which span 
the width of the capsid shell. These pores often occur at symmetry axes. The pore surface 
has largely been ignored as a means of functionalizing the capsid. I demonstrate that capsid 
pores can be modified via mutagenesis to provide a simple and remarkably strong binding 
site to allow for the multivalent display of a guest molecule on the capsid's outer surface. 
These results have implications for the use of capsids as drug delivery vehicles and 
nanoreactors. 
Finally, in Chapter 4, I build on previous work done in this lab which sought to 
engineer a redox-based switch for control over capsid assembly. The effects of the size and 
shape of various adducts on the ability of the capsid to assemble are explored and the results 
demonstrate the significant plasticity of the three-fold symmetric interface. Further, one 
adduct was found to disassemble completely upon lowering the pH, providing a combined 
redox-pH switch. These approaches show potential for enhancing control over capsid 
assembly which is a highly desirable function to have for any nanotechnology application 
of protein capsids. 
Overall, this work has added new tools to the nanotechnology toolbox by 
highlighting the utility of the pore surface as a supramolecular assembly site and expanding 
understanding of redox and pH switchable control over capsid assembly. In addition, my 
work suggests that future exploration of the effects of the electrostatic environment within 
the capsid on encapsulated enzyme kinetics could significantly enhance our understanding 





EFFECTS OF ENCAPSULATION UPON THE KINETIC PARAMETERS  















Compartmentalization or encapsulation as a means of protecting molecules and 
controlling reactions is a strategy successfully employed by nature on several levels. At the 
microscale, cell organelles have evolved to protect critical components such as DNA 
(nucleus), to isolate otherwise dangerous molecules such as proteases (lysozome), and to 
precisely control reaction cascades (mitochondria). Natural encapsulation methods have 
been extremely effective at the nanoscale as well. 
Viral capsids are perhaps the most well-known example of nanoscale 
compartmentalization. These capsids are significantly functionalized to protect and deliver 
their genomic material, often to highly specific targets. The fact that all viruses are 
comprised of some form of capsid is a strong indicator of how effective encapsulation can 
be at protecting and controlling reactive molecules. Other, nonviral, capsids have also 
proven useful to nature.  
Nanoreactors such as the carboxysome or some fatty acid synthases have evolved 
to house the multiple enzymes necessary to carry out their functions.136,137 By sequestering 
together these enzymes, the nanoreactors greatly enhance the overall rate of reaction of the 
cascade.42,138 In the bacterium Bacillus subtilis, a nanoreactor has evolved in which 
lumazine synthase, the enzyme responsible for the penultimate step of riboflavin synthesis, 
encapsulates the next enzyme in the pathway, riboflavin synthase.139,140 The constrained 
proximity of the sequentially active enzymes allows for rapid progression through the last 
two steps of the synthetic pathway.50 
Given how successful encapsulation strategies have been in nature, it is no surprise 




how to improve upon existing capsids and one day hope to be able to generate them de 
novo. Protein capsids have shown significant promise for use as drug-delivery 
vehicles,141-145 contrast agents for bioimaging,111,146–149 biomineralization 
templates,113,150-154 and synthetic nanoreactors.60,62,65,122–124,126–130,133,155,156 
Aquifex aeolicus is an extremophilic bacterium first identified from samples 
collected near submerged volcanic vents around Sicily. As a thermophile, its proteins have 
evolved to maintain stability and function at high temperatures.157 The lumazine synthase 
complex isolated from this organism (AaLS) exists as a 60 subunit protein capsid which 
has shown itself to be singularly appealing as an engineering scaffold due to its inherently 
high stability and corresponding tolerance toward mutation.131 
The AaLS capsid forms as a dodecamer of pentamers that possesses pores at the 
five-fold symmetry axes which span the width of the capsid shell. These pores are thought 
to allow influx and efflux of small molecules through the capsid. This is evinced by the 
observation that the active site is located on the interior surface of the capsid. Therefore, it 
should be possible to engineer the capsid to selectively encapsulate a guest enzyme and to 
measure the difference in activity between the free and encapsulated forms. Indeed, 
previous work has shown that the capsid can be altered through directed evolution to 
achieve successful encapsulation of either deca-arginine tagged green fluorescent protein 
(GFP) or an identically tagged HIV protease through charge complementarity-based 
interactions.63,64,133 The most effective of the evolved capsids, termed AaLS-13, possessed 
mutations imparting it with a significantly negatively charged interior surface. 
Encapsulated GFP was seen to fluoresce at similar levels to the unencapsulated 




thus it was believed that the protease would be active within the capsid. However, no 
protease activity was observed in the encapsulated protease samples. This apparent 
inactivity may be due to inhibition of the protease by the capsid, but a reexamination of the 
properties of both proteins revealed a more likely culprit.  
The protease is most active at a pH around 4, but the capsid precipitates at these pH 
levels; therefore, the experiments were carried out at pH 8, where the capsid is most stable. 
Unfortunately, HIV protease is only minimally active at this pH. Thus, although 
encapsulation was successfully achieved, HIV protease was not a suitable enzyme for 
measuring the effects of encapsulation on enzymatic activity.  
In this chapter, we seek to demonstrate that an enzyme which is active at the 
optimum pH for capsid stability (pH 8) does, in fact, remain active upon encapsulation. 
Additionally, the kinetic parameters of the free and encapsulated enzymes will be examined 
to determine what effect, if any, sequestration within the capsid has upon these values. 
The guest enzyme we chose, which exhibits maximum activity at pH 8, is a 
carboxylesterase isolated from another thermophilic bacterium, Geobacillus 
stearothermophilus (Est55, PDBID: 2OGT).158,159 It is a promiscuous enzyme that acts on 
a variety of different ester substrates, including 4-nitrophenyl acetate (PNPA). This 
substrate was specifically chosen because it is small enough to enter the capsid and one of 
the cleavage products, nitrophenolate, absorbs strongly at 405 nm. This allows for 






2.2.1. Design of an Esterase Encapsulation System 
Based on an existing deca-arginine tag (R10) method of achieving encapsulation,
63 
an R10 tag was appended to the C-terminus of Est55 to produce a mutant esterase (Est55-
R10) which was then coproduced in the presence of AaLS-13. It was expected that Est55-
R10 would be electrostatically attracted to the assembling capsid in vivo which would result 
in the formation of a complex and encapsulation of the esterase (Figure 2.1). The complex 
should then exhibit a much higher degree of esterase activity than the capsid alone.  
2.2.2. Encapsulation of the Esterase by the Capsid 
Est55-R10 and AaLS-13 were over-produced in E. coli cells both individually and 
together. After purification, all proteins were analyzed via SEC. The activity of the eluted 
fractions obtained from the purification of AaLS-13 alone and coproduced with Est55- R10 
was examined as an initial assessment of whether or not encapsulation had occurred. There 
is significantly more esterase activity in the capsid fractions obtained from the coproduced 
sample than in those from the capsid alone (Figure 2.2), indicating an association between 
the capsid and the tagged esterase.  
SDS-PAGE was performed to confirm the presence of both proteins in the 
coproduced sample (Figure 2.3). A band corresponding to the calculated molecular weight 
of the tagged esterase (56.7 kDa) was observed at the expected position. The AaLS-13 
capsid monomer (17.7 kDa) is known to migrate anomalously and is typically observed at 
a distance corresponding to a protein of approximately 18.5 kDa, which is where the largest 






Figure 2.1. Schematic representation of the encapsulation of Est55-R10 by AaLS-13. The 
positively charged deca-arginine tag is electrostatically attracted to the negatively charged 



















Figure 2.2. UV absorbance and esterase activity of SEC fractions from AaLS-13 capsid 
produced alone (A) or coproduced with Est55-R10 (B). Fractions were obtained via SEC 



















Figure 2.3. SDS-PAGE analysis of esterase encapsulation. After purification, a sample of 
AaLS-13 that had been coproduced with Est55-R10 was analyzed by SDS-PAGE. The 









Est55-R10 were excised and their identities confirmed by mass spectrometry. Several other 
bands were also excised and mass spectrometry analysis showed these were similar to the 
endogenous E.coli proteins previously shown to be encapsulated.133 
2.2.3. Quantification of the Encapsulation of Est55-R10 
To quantify the amount of Est55-R10 and AaLS-13 present in the purified complex, 
the bands corresponding to these proteins were excised from the SDS-PAGE gel. After 
excision, protein was extracted from the gel and digested via protease treatment. The 
resulting peptide fragments were doped with a known quantity of two different 13C labeled 
peptide standards, one whose sequence matched the capsid and one which matched the 
esterase. The amount of protein present in a given band was estimated by comparing the 
size of the unlabeled peptide peak to its labeled counter-part (Figure 2.4). This calculation 
yielded an average of 2.1 esterases encapsulated per capsid. From this value, we calculated 
a mass ratio of Est55-R10 : Total protein of 0.0284. Total protein is defined as the sum of 
the masses of one AaLS-13 capsid (240 monomers) and 2.1 Est55-R10's. With this 
information, it became possible to calculate the exact amount of Est55-R10 present in each 
encapsulation sample and thus to differentiate between the specific activity of the sample 
as a whole (esterase and capsid) and that of the encapsulated esterase alone. 
2.2.4. Specific Activity of the Free and Encapsulated Esterase 
The specific activities of untagged Est55 and Est55-R10 produced alone and in 
combination with AaLS-WT or AaLS-13 are shown in Table 2.1. The individual esterases 








Figure 2.4 LC-MS/MS spectra of the excised SDS-PAGE bands. A known quantity of the 
13C – labeled standard was doped into each sample. The mass peaks of unlabeled peptide 
fragments resulting from proteolytic digest of AaLS-13 (a) or Est55-R10 (b) as well as their 
respective 13C labeled counter-parts are indicated by arrows. The amount of AaLS-13 and 
Est55-R10 in the encapsulation complex was estimated by comparing the peak areas of the 













Table 2.1 Specific activities of various combinations of capsid and esterase.  
 
Protein(s) Specific Activity  
(µmol/min/mg total protein) 
Specific Activitya,b  
(µmol/min/mg esterase) 
Est55 325 ± 13 325 ± 13 
Est55-R10 192 ± 35 192 ± 35 
AaLS-WT 0.0045 ± 0.00024 n/a 
AaLS-13 0.0040 ± 0.0019 n/a 
Est55 + AaLS-13 0.053 ± 0.0003 n.d. 
Est55-R10 + AaLS-WT 0.076 ± 0.047 n.d. 
Est55-R10 + AaLS-13 0.29 ± 0.06 10 ± 2 












appears to decrease the specific activity of the resulting mutant by approximately 40%.  
This decrease in activity may be due to mechanical screening by the R10 tag as the 
C-terminus is located near the active site. Presumably, the tag is free to move around in 
solution in front of the active site and may deflect substrate prior to binding. Both the 
wild-type and mutant capsids show virtually no esterase activity by themselves.  
Coproduction of Est55 with AaLS-13 or of Est55-R10 with AaLS-WT results in a 
pooled capsid peak with a specific activity that is approximately 10-fold higher than that 
of the capsid peaks from either capsid when they are produced alone, suggesting that some 
degree of encapsulation or association naturally occurs between these proteins. The 
specific activity of the capsid peak obtained from the coproduction of Est55-R10 with 
AaLS-13, however, is 100-fold higher than that of the capsid alone, indicating a much 
higher degree of association. This increased activity is likely due to charge 
complementarity between the cationic tag and the highly negatively charged interior of 
AaLS-13. The specific activity of the encapsulated esterase was determined to be 
approximately 20-fold lower than the unencapsulated form. 
2.2.5. Michaelis-Menten Kinetics 
In order to determine how encapsulation affects the kinetic parameters of the 
esterase, Michaelis-Menten kinetics were measured in order to determine what affect, if 
any, encapsulation had upon the activity of the esterase (Figure 2.5). The estimated 
confinement kcat (kcat, conf) for encapsulated Est55-R10 is approximately 30-fold lower than 
that of free Est55-R10 which suggests a diminished ability for each molecule of 












Figure 2.5. Michaelis-Menten kinetics of the free (A) and encapsulated (B) esterase. The 
initial velocity of PNPA hydrolysis was measured spectrophotometrically in buffer at 25 












encapsulated esterase was also lower in comparison to the free esterase, with the 
encapsulated Km, conf being approximately half that of the free esterase. In terms of the 
turnover number or catalytic efficiency of the enzyme, the significant decrease observed 
in the kcat of the encapsulated esterase is partially counterbalanced by a concurrent drop 
in the Km, conf. This offset resulted in an encapsulated Est55-R10 efficiency that was only a 
single order of magnitude lower than that of the free enzyme. 
2.3 Discussion 
Encapsulation of enzymes within a proteinaceous shell allows for control over 
substrate access, increases the concentration of pathway intermediates, and can perturb the 
kinetic parameters of the confined enzymes. In this study, we found that the use of a charge 
complementarity-based loading method, previously developed to encapsulate an R10 
tagged HIV protease in the same capsid, resulted in an average in vivo loading capacity of 
2.1 Est55-R10 molecules per AaLS-13 capsid. The loading capacity of HIV protease-R10 
was approximately seven-fold higher with an average of seven HIV protease-R10 dimers 
per capsid.133 There are several factors that could potentially contribute to the elevated 
protease loading, including size, inherent pI, quaternary structure differences, and 
production levels between the two enzymes. 
Est55-R10 exists as a 510 residue, approximately 57 kDa monomer with an 
estimated pI of 6.8 while HIV protease-R10 is a dimer composed of two separate 99 residue, 
12 kDa monomers with an estimated pImonomer of 11.1. Thus, we can see that the esterase is 
significantly larger than the protease dimer and is also much more negatively charged. The 




loading of the esterase. Additionally, charge repulsion between the negatively charged 
lumenal capsid surface and the esterase surface may have decreased loading of the esterase. 
Charge neutralization between the same capsid surface and the protease may have 
enhanced protease loading. Avidity effects are likely to have played a significant role in 
the greater protease loading as the tagged dimer has 20 positive charges in close proximity 
while the tagged esterase has only 10 such charges.  
Encapsulation of the esterase decreased Km, conf and kcat, conf by approximately 2-fold 
and 30-fold, respectively, with the overall catalytic efficiency (kcat, conf/Km, conf) decreasing 
by an order of magnitude. These effects are similar to those observed in native and other 
engineered encapsulation systems. 
In nature, the lumazine synthase from Bacillus subtilis (BsLS) encapsulates a trimer 
of its own riboflavin synthase (BsRS) and thereby confines the last two steps in the 
riboflavin synthesis pathway together.140 When examined individually, encapsulation 
actually increases the Km values of both BsLS and BsRS for their respective substrates 
while also reducing their maximum velocities. However, a comparison of the rate of 
riboflavin production of the complex versus a mixture of the BsLS capsid and 
unencapsulated BsRS trimer indicates the complex produces riboflavin nearly twice as 
fast.50 This rate enhancement is thought to be due to substrate channeling as result of the 
close proximity of the BsLS and BsRS active sites. Thus, even though their individual 
kinetic parameters appear to be functioning less efficiently, encapsulation of BsRS by 
BsLS allows for a significant enhancement to the overall rate of the pathway at the lower 
substrate concentrations found within the cell. A similar result is seen in the larger protein 




associations of capsid subunits often encapsulate several enzymes from a single metabolic 
pathway.136,160,161 
The carboxysome is one of the most extensively studied BMCs. It contains carbonic 
anhydrase (CA) and ribulose-1,5-bisphosphate carboxylase/oxygenase (RuBisCO), the key 
enzymes in the carbon fixation pathway. Confinement of RuBisCO within the 
carboxysome does not significantly alter its reaction kinetics, presumably due to its 
inherent poor efficiency, but it does prevent competitive inhibition by O2 via substrate 
gating since the capsid does not allow O2 into the lumen.
42,162,163 CA, on the other hand, is 
approximately 3-fold faster in the cytosol than in the carboxysome. Experiments in which 
CA was produced in the cytosol significantly reduced RuBisCO activity because the CO2 
produced outside the capsid left the cell at a much faster rate than it diffused into the 
carboxysome.138 Thus, the only way to effectively pair CA and RuBisCo is to co-
encapsulate them, despite the reduction in activity suffered by CA.  
In an effort to understand the effects of encapsulation upon enzyme kinetics, several 
novel encapsulation systems have been developed. All of these systems employ viral 
capsids,60,62,123,130,155 except for one which used a bacterial capsid.133 Several different 
loading methods have been used to achieve encapsulation of a guest protein, including 
covalent (genetic or chemical fusion to a naturally encapsulated molecule) and noncovalent 
(electrostatic) techniques. Regardless of the means used to load the capsid, the specific 
identity of the capsid or the guest enzyme, encapsulation of a single species had remarkably 
similar effects on the kinetic parameters of the enzyme. 
For all of the experiments in which kinetic parameters were determined, 




magnitude. A few encapsulated enzymes showed no significant change in activity 
compared to their free forms. The Km, conf, however, was typically unchanged or very 
slightly decreased in relation to the free enzyme. These decreases may have been the result 
of an accumulation of substrate within the capsid (Mconf) relative to the substrate 
concentration in the bulk solvent. Overall, encapsulation typically decreased the turnover 
number (kcat/Km) by approximately an order of magnitude. 
Experiments regarding the effects of crowding agents on enzyme activity in 
solution have shown that crowding agents typically cause a significant decrease in Km and 
have varying effects on kcat, depending on the enzyme being studied, with the turnover 
number increasing significantly in most cases.164 These results generally agree well with 
the observed effects of encapsulation in both naturally occurring and engineered 
nanoreactors. However, we noted three exceptions in which Km, conf was observed to 
increase as a result of engineered encapsulation. 
In one of these cases, the increase was attributed to over-crowding.60 A nanoreactor 
designed to use the bacteriophage Qß capsid to encapsulate firefly luciferase resulted in an 
increased Km, conf for both the substrate luciferin and the cofactor ATP. This increase scaled 
directly with the number of enzymes loaded per capsid.  
In the second case, another bacteriophage capsid, P22, was used to encapsulate an 
alcohol dehydrogenase.130 The researchers studied the effects of encapsulation for all three 
capsid forms and noted that, while the Km, conf of the substrate was decreased for all three 
forms, the Km, conf of the cofactor, NADH, was increased under certain conditions. No 





The third case of an increase in Km, conf was a result of experiments designed to 
determine the effects of the electrostatic nature of capsid pores on the ability of small 
molecules to enter and exit the capsid.124 Another bacteriophage, MS2, was engineered to 
encapsulate an alkaline phosphatase (PhoA) by genetically appending a negative tag to the 
enzyme, much like the R10 tag we added to Est55. When the pores were engineered to have 
the same charge as the substrate, an almost 6-fold increase in Km, conf was observed with a 
concurrent 3-fold decrease in kcat, conf. Pores with the opposite or neutral charge had little 
or no effect on the measured kinetics. These results demonstrate that the electrostatic nature 
of the pore can play a significant role in altering encapsulated enzyme kinetics. 
Although it is known that the AaLS-13 capsid has a negatively charged interior 
surface,133 no structure is available to elucidate the nature of its pores. For the encapsulation 
of Est55-R10, it is possible that the pores are slowing the rate of substrate diffusion into the 
capsid, thereby lowering the kcat, conf. If such substrate gating was responsible, we would 
expect to see a concurrent increase in Km, conf due to the decreased diffusion of the substrate 
into the capsid, as was previously observed with PhoA. However, both Km, conf and kcat, conf 
decreased in comparison to the unencapsulated parameters. This difference suggests that 
substrate gating is not playing a significant role in the kinetics of our nanoreactor system. 
Alternatively, we speculate that the electrostatic environment within the capsid lumen 
could alter the rate of release of product from the enzyme.  
Electrostatic interactions have been shown to alter reaction rates through both 
substrate attraction165,166 and intramolecular active site transfer in bifunctional enzymes or 
fusion proteins.167 These effects are typically a rate enhancement achieved through 




to the active site. Mutagenesis studies in which these types of interactions were abolished 
or rendered unfavorable via charge neutralization or reversal demonstrate the potential of 
electrostatic interactions to modulate protein activity.168–170  
In the case of the AaLS-13 encapsulated esterase, it is plausible that the highly 
anionic nature of the capsid interior could electrostatically influence several different 
aspects of the catalytic mechanism such as inhibiting activation of the catalytic serine 194 
or altering the stability of the transition state. It may also suppress release of the negatively 
charged acetate and nitrophenolate products from the esterase, yielding a lower Vmax and 
thus a lower kcat, conf. It is possible that a similar interaction is occurring in the nanoreactors 
engineered from viral capsids since they inherently possess highly positively charged 
lumenal surfaces to bind their genomes. Encapsulation systems which rely on fusion with 
the viral genome or scaffold proteins may neutralize some or all of the interior charges and 
thereby reduce or abolish their effects on the confined enzymes. In some cases, the ratio of 
genomic negative charge to capsid positive charged can exceed 1:1, meaning that use of 
viral genomic material as an encapsulation tag may even result in negative supercharging 
of the capsid interior.171 These Coulombic interactions could potentially alter the Km,conf as 
well. 
Consider two potential scenarios. The first scenario has a substrate and capsid 
interior that are complementarily charged while the second has both components possessed 
of the same charge. In the first scenario, the enzyme must compete with the capsid surface 
to bind substrate. This competition will likely cause an increase in Km,conf. The second 
scenario may see a decrease in Km,conf because binding of the substrate, which is neutral 




repulsion between the substrate and interior capsid surface.  
Alternatively, if the substrate is capable of diffusing into the capsid at a faster rate 
than it diffuses out, then it is possible that the decreased Km, conf is due to an increase in the 
Mconf of the substrate resulting from the local accumulation of substrate molecules within 
the capsid. This increase in effective concentration also applies to the encapsulated 
esterase. Given our calculated loading capacity of 2.1 esterases per capsid, we estimate the 
Mconf of the esterase to be approximately 300 µM. Although we cannot calculate the 
substrate Mconf, the fact that the encapsulated esterase kinetics fit well to the Michaelis-
Menten equation suggests it must be significantly higher than the Mconf of the esterase, so 
as not to violate the steady-state assumption.172  
Further, these elevated concentrations may have led to a change in the intrinsic 
thermodynamic activity coefficients of the substrate and/or esterase. As the concentration 
of an electrolyte increases, its thermodynamic activity deviates from ideality. These 
deviations could greatly alter the kinetics of the reaction. In at least one case, the kinetic 
parameter alterations caused by a crowding agent were attributed to a change in activity 
coefficients.173 Such changes could also be the result of alterations to the way the 
encapsulated enzyme or substrate are solvated in comparison to the bulk solvent. 
There are fewer water molecules inside the AaLS-13 capsid than in the bulk solvent 
and, presumably, they are more highly ordered due to the significant negative charge of the 
lumenal surface.174 Given that our encapsulation system relies upon charge neutralization, 
the tagged esterase is mostly likely very near the interior capsid surface and therefore may 
be surrounded by a higher degree of ordered water molecules than when it is floating free 




in turn, alter its intrinsic activity.  
Our work demonstrates that a charge complementarity-based encapsulation method 
does not necessarily abolish the function of the tagged guest enzyme. Further, we 
demonstrated that noncovalent encapsulation methods are a viable means of quickly and 
easily producing a novel nanoreactor system. This system has the potential for further 
functionalization through mutagenic alteration of unreactive interior capsid residues to 
those capable of easily undergoing covalent modification such as cysteine, lysine, or 
tyrosine. Such alteration potentially allows for the creation of heteroenzyme nanoreactors 
composed of both covalently and ionically loaded guest enzymes. Finally, this work serves 
to highlight the fact that electrostatic influences of the capsid upon the function of the 
encapsulated guest enzyme are poorly understood and merit further study. 
2.4. Materials and Methods 
2.4.1. Materials 
All cell culture media and chemical reagents were purchased from Bio-rad, Fisher 
Scientific, Gold Biotechnology, or Pierce Biotechnology and used without further 
purification. Pfu-turbo DNA polymerase and E. coli cell strains BL21 (DE3) and XL1-
Blue were purchased from Stratagene. T4 DNA ligase and all restriction endonucleases 
were purchased from New England Biolabs. The oligonucleotides used in this study were 





2.4.2. Production and Purification of Crude Protein 
All proteins were produced in CaCl2-competent BL21 (DE3) E. coli cells. 
Transformation of the gene-bearing plasmids (pACYC-Est55, pACYC-Est55-R10, 
pMG-AaLS-13) either individually or in combination was accomplished via heat shock at 
42 °C for 2 minutes. The cells were then grown at 37 °C for 1 hour and plated on antibiotic-
containing LB agar plates (50 µg/mL chloramphenicol (CAM) for Est55 or Est55-R10, 
100 µg/mL ampicillin (AMP) for AaLS-13, both antibiotics for in vivo coproduction). The 
plates were grown overnight in a 37 °C oven. A single colony was selected from the plate 
and used to inoculate a 7.5 mL antibiotic-containing LB culture which was then grown 
overnight at 37 °C with shaking at 250 rpm. An aliquot of this culture (1 mL) was then 
used to inoculate antibiotic-containing LB media (500 mL). Over-production of the desired 
protein was achieved by growing this large culture at 37 °C to an OD600 of 0.7, inducing 
production by adding IPTG to a final concentration of 0.2 mM, and then incubating the 
cultures at 30 °C for 20 hours at 250 rpm. Co-expressed cultures containing AaLS-13 and 
Est55-R10 where incubated at 37 °C  for 4 hours, postinduction. The cells were harvested 
via centrifugation in a Sorvall RC 6+ centrifuge with a Fiberlite F10 6x500y rotor 
(6000 rpm for 15 minutes at 4 °C). Pellets were frozen at -80 °C until used. 
Cell pellets were resuspended in 10 mL of lysis buffer (50 mM sodium phosphate, 
300 mM NaCl, pH 8.0). The cells were lysed by incubation with lysozyme (10 mg), RNase 
A (1.2 mg), and DNase I (20 µg) on ice for 1 hour followed by sonication at 45 µm 
amplitude for 3 minutes in 10 second on/off pulses using a Misonix ultrasonic liquid 
processor. The lysate was then clarified by centrifugation in a Sorvall RC 6+ centrifuge 




2.4.3. Purification of AaLS Capsid 
For purification of AaLS-WT, AaLS-13, or coproduction samples, the supernatant 
was loaded onto a Ni2+-NTA resin which had been equilibrated with lysis buffer and 
incubated for 1 hour at 4 °C with gentle rocking. The column was then washed with lysis 
buffer, lysis buffer containing 40 mM imidazole, and lysis buffer containing 500 mM 
imidazole. The high imidazole fraction was then concentrated and either run on the FPLC 
immediately (AaLS-WT) or dialyzed into lysis buffer containing 5 mM EDTA overnight 
and then run on the FPLC (AaLS-13 and coproduction samples). The assembled capsid 
was isolated by loading the sample onto an ÄKTA FPLC system (GE Healthcare) equipped 
with a HiPrep 16/60 Sephacryl S-400HR column and run with lysis buffer containing 5 
mM EDTA at 4 °C at a flow rate of 0.5 mL/min. 
2.4.4. Purification of Est55 and Est55-R10 
For purification of Est55 or Est55-R10 produced in the absence of an AaLS variant, 
the clarified lysate was dialyzed into ion exchange buffer A (50 mM sodium phosphate, 
20 mM NaCl, pH 8.0) overnight at 4 °C. The sample was then loaded onto the FPLC 
equipped with either an anion-exchange MonoQ 5/50 GL column (Est55) or a cation-
exchange MonoS 5/50 GL column (Est55-R10) which had been equilibrated with ion 
exchange buffer A. Bound protein was eluted using a 20 mL gradient ranging from 0% to 
100% ion exchange buffer B (50 mM sodium phosphate, 1M NaCl, pH 8.0) run at 4 °C. 
SDS-PAGE with a Thermo Scientific Unstained Molecular Weight Marker was then used 
to determine which fractions contained the esterase. These fractions were pooled, 




buffer at 4 °C. Est55R10 production typically yielded 16 mg/L culture. Purity was assessed 
by SDS-PAGE. 
2.4.5. Activity and Kinetics Assays 
To determine the activity of the enzymes used in this study, the hydrolysis of p-
nitrophenyl acetate to p-nitrophenolate and acetate was followed spectrophotometrically 
using a Hitachi U-3310 by observing the change in absorbance at 405 nm. Assays were 
conducted in triplicate using a final total protein concentration of 1.2 nM. Various 
concentrations of PNPA stock solutions were prepared in 95% ethanol such that the 
addition of 10 µL of PNPA stock and 4 µL of protein stock to 1986 µL of lysis buffer 
resulted in estimated final concentrations of 25, 50, 100, 200, 400, or 800 uM in the reaction 
cuvette. Actual substrate concentrations were determined by quenching the reaction with 
concentrated NaOH. After the addition of PNPA and protein, the reaction was monitored 
for 500 seconds with readings taken every 0.1 seconds. Using the slope of the linear portion 
of the resulting curve (Δabsorbance/s), the Beer-Lambert law, and the extinction 
coefficient of p-nitrophenol at 405 nm (17800 M-1cm-1), the reaction velocity (M/s) and 
specific activity (µmol/min/mg protein) were determined. Protein concentration was 
determined via Bradford assay. 
2.4.6. Identification and Quantification of Encapsulated Est55-R10 
Direct detection of Est55-R10 in coproduced samples was initially accomplished 
using SDS-PAGE. Samples showing the presence of both Est55-R10 and AaLS-13 were 




LC-MS/MS. Samples were divided into 50 µL aliquots and treated with 5 µL 1% 
ProteaseMax (Promega) for 5 minutes before being vortexed and diluted with 15 µL of 
50 mM ammonium bicarbonate (ABC). Finally, 30 µL of 20 ng/µL trypsin/lys-C solution 
in 50 mM ABC was added to the sample which was then thoroughly mixed and incubated 
for 5 hours prior to injection on an LTQ-FT (Thermoelectron) mass spectrometer.  
Identification of esterase and capsid proteins was confirmed by comparison to 
sequences in the NCBI database and the previously determined sequence of the AaLS-13 
capsid.133 Quantification of both proteins was accomplished by doping samples with 
known amounts of 13C-labeled peptide fragment standards (Table 2.2). The standards 
contained eight 13C atoms each. The concentration of each standard was determined by 
amino acid analysis and by absorbance at 205 nm. Amino acid analysis was conducted by 










Table 2.2. Sequences of 13C labeled peptide fragments used for quantification of the capsid 
and esterase from coproduced samples. Molecular weights given for the +2 charge state. 
 




Extinction Coefficient at 
205 nm (M-1 cm-1) 
Est55-R10 AMLQSGSGSLLLR 1333.5 36940 
























MULTIVALENT DISPLAY OF A PROTEIN ON THE EXTERIOR SURFACE OF A 





Nearly all proteins associate into multimeric assemblies in their active form.6 The 
highly symmetric nature of many of these supramolecular complexes typically results in 
the multivalent display of one or more proteins on the outer surface of the complex.12 When 
these proteins serve to bind other assemblies or large molecules via multiple interfaces, 
this display results in a significant increase in the effective affinity, or avidity, between 
them. Due to their potential to augment functions which require binding to a large molecule 
or surface, avidity enhancing effects are one of the most common benefits of 
supramolecular assembly. 
Viral capsids are composed of many copies of one or more proteins, usually 
symmetrically arranged as hollow polyhedrons. This architecture imparts significant 
stability and protection to their genomes while affording an excellent platform for the 
multivalent display of receptor binding proteins. The avidity effects of this display greatly 
improve the virus’ ability to target and enter specific cells,175–177 although this can also be 
a problem for the virus as the same display improves the ability of antibodies to bind to its 
surface. Enhancement of avidity can also be beneficial to catalysis. 
Cellulosomes are a collection of carbohydrate-active enzymes (CAZymes) 
produced by bacteria which digest plant cell wall polysaccharides.178 Multiple copies of 
these enzymes are linked to a display platform, known as a scaffoldin, through docking 
proteins which display KD values in the nanomolar range.
179 This assembly is significantly 
more efficient at degrading native cellulose than the monomeric CAZymes.180 Researchers 
have already capitalized on the discovery of these very selective, high affinity complexes 




biosensors, and fusion proteins designed to impart new catalytic function to the complex.181  
As our understanding of how to manipulate and alter the supramolecular assembly 
of proteins becomes more sophisticated, so too do the applications of this knowledge. 
Among recent advances, a protein scaffold of unknown native function was 
computationally converted into a potent inhibitor of hen egg lysozyme,182 the 
Methanoccocus maripaludis group-II chaperonin capsid opening and closing reaction was 
redesigned from a chemically driven process to a photoreactive one through the covalent 
modification of engineered cysteine pairs by azobenzene-dimaleimide,183 and a 
cytochrome (cb562) bearing no relation to any known metallo-ß-lactamase was manipulated 
into a fully functional member of that enzyme class through the use of metal templated 
interface redesign.184 In this chapter, we seek to further expand the variety of available 
supramolecular assembly techniques by functionalizing the pores of a bacterial protein 
capsid. 
Aquifex aeolicus lumazine synthase (AaLS) is an extremely stable protein capsid 
making it attractive as a scaffold for supramolecular assembly. Previous work has 
generated mutant versions of the capsid with a variety of different properties including 
changes in assembly state, size, and interior surface charge.63,133–135 A mutant with an 
overwhelmingly positive lumenal surface has been shown to encapsulate RNA via charge 
complementarity during in vivo assembly.134 In another study, it was demonstrated that a 
capsid variant with a negatively charged interior surface could be loaded with positively 
charged guest molecules, also driven by charge neutralization.63,64,133  
On the basis of this previous work, we propose a novel means of noncovalently 




deca-arginine (R10) tagged guest protein and a mutant AaLS capsid engineered to have 
negatively charged five-fold axial pores. This negative pore surface serves as a means of 
inducing the positively charged tail of the R10 tagged protein to thread through and bind to 
the pore, thus providing a multivalent presentation of the tagged protein on the outer 
surface of the capsid (Figure 3.1). We report here a proof-of-principle that capsid pores, 
which have been previously ignored as supramolecular assembly interfaces, may be 
functionalized through mutagenic manipulation of their electrostatic surface. 
3.2. Results 
3.2.1. Development of a Charge Complementarity Based Method  
of Decorating the Outer Surface of the AaLS Capsid 
The wild-type AaLS five-fold axial pore only possesses a net charge of -5 so we sought to 
mutate residues lining the pore to increase its negative character. The initial design of the 
negatively super-charged pore called for four of the five residues whose sidechains 
protrude into the pore to be mutated to aspartates (S94, K98, N102, E106) (Figure 1.1b). 
The first position (D90) is an aspartate in the wild-type sequence and therefore did not need 
to be mutated. A sixth residue, R108, was also mutated to aspartate, despite the fact that its 
sidechain does not enter the pore itself. This was done in the hopes that the residue, which 
protrudes into the bulk solvent on the outer surface of the pore, would enhance attraction 
of the R10 tag to the pore surface and facilitate threading of the tag through the pore. The 
capsid variant containing these five mutations was labeled AaLS-6D and possessed a 
negatively super-charged pore with an estimated -25 charge. In order to make any 













Figure 3.1. Schematic representation of the assembly of the tag-pore complex. Upon 
mixing, charge complementarity will allow the deca-arginine tag on GFP (blue pluses) to 
thread through the negatively supercharged pores (red circles) resulting in a uniform, 










GFP was selected for use as the R10 tagged protein (GFP-R10). 
 
3.2.2. Estimated Packing Density of the Tag-Pore Complex 
Using the program Mole 2.0, which is specifically designed to measure the volume 
of protein cavities, and the crystal structure of the AaLS capsid, we estimated the volume 
bounded by the backbones of the pore helices to be approximately 3733 Å3 (Figure 1.1c). 
Using previously reported amino acid volumes.185 We estimated the volume of a single 
aspartate sidechain to be 59 Å3. Given that there are five aspartates per helix and five 
helices per pore, a total of 25 aspartate sidechains protrude into each pore with a total 
volume of 1475 Å3. If the R10 tag adopts an extended conformation upon threading through 
the pore, then only seven arginine residues will be required to span the pore. Again using 
previously reported values, we estimate the total volume of the sidechains and backbone 
to be approximately 1575 Å3. Thus, the combined volume of the aspartate sidechains and 
the tag residues threading through the pore is 3050 Å3 yielding a packing density of 0.80. 
This packing density is slightly above the maximum crystallographic packing density of 
0.74 but not unreasonable given our simplified volume estimates and suggests excellent 
contact between the tag and pore. 
3.2.3. Fluorescence Detectable in AaLS-6D Capsid Peak Fractions  
Following Incubation with GFP-R10 
In order to test whether or not GFP-R10 associates with AaLS-6D differently from 
the wild-type capsid, the following mixtures were produced and analyzed: 




where purified in high ionic strength running buffer (525 mM), combined at a molar ratio 
of 72:1 GFP:capsid, then dialyzed overnight at 4 °C into 275 mM ionic strength running 
buffer. The components of each mixture were then separated via SEC and the fluorescence 
emission at 507 nm and UV absorption at 280 nm measured for each fraction eluted from 
the column (Figure 3.2). Each of the various mixture components was also run over the 
SEC individually to allow for comparisons between the single component and mixture 
chromatograms. 
The wild-type and mutant capsid peaks both elute at the same volume, suggesting 
that they are the same size and therefore, the mutations introduced to the pore did not 
significantly alter the quaternary structure of the capsid. This conclusion is further 
supported by TEM (Figure 3.3). The size of the wild-type and mutant capsids was 
estimated at 17.4 ± 3.6 nm and 16.2 ± 2.4 nm, respectively. The 6D capsid does seem to 
be less stable, though, as it exhibits a small second peak which corresponds to the volume 
at which lesser oligomerization states of the capsid elute.  
GFP-R10 elutes off of a sephacryl S400 column significantly later than the untagged 
variant and with a much broader peak. This elution volume is actually greater than the 
column volume and is likely due to interactions between the inherently sticky R10 tag and 
the column matrix. When mixed with either capsid, a peak was seen for each GFP variant 
at the same volume as when that variant was run individually (Fig 3.2a and 3.2b). All 
controls showed identical fluorescence patterns to the individually run GFP variant (data 
not shown). No fluorescence was visible to the naked eye in the capsid peak fractions from 
either control; however, a very small amount of fluorescence was detected via fluorimeter 





Figure 3.2. Fluorescence and A280 measurements of SEC fractions from different GFP and 
capsid combinations. Samples were mixed at a ratio of 72:1 GFP:capsid and run in 20 mM 
Tris, 250 mM NaCl, 5 mM EDTA, pH 8 buffer. The position of the 60 subunit capsid and 



















Figure 3.3. TEM images of the wild-type AaLS (A), AaLS-6D (B), and 












to the inability of the column used to obtain baseline separation of these two proteins. When 
both GFP-R10 and AaLS-6D were present, the capsid peak was brightly fluorescent to the 
naked eye and eluted slightly earlier than the mutant capsid alone. These are both good 
indicators of an association between the two components. 
3.2.4. SDS-PAGE of Capsid Peak Fractions Shows Significant 
GFP-R10 Co-Elution with the AaLS-6D Capsid 
To determine what proteins were present in the capsid peak fractions of the various 
mixtures, an SDS-PAGE was performed on these fractions. The SDS-PAGE of the 
GFP- R10 + AaLS-WT fractions shows only a single band for the capsid peak fractions of 
the expected size for the AaLS monomer (Figure 3.4). The GFP-R10 peak fractions also 
show a single band of the expected size. The GFP + AaLS-6D capsid peak fraction, in 
keeping with the fluorescence and UV results, shows a tiny amount of GFP present, relative 
to the amount of capsid protein. Only one band, corresponding to GFP, is observed in the 
GFP peak fractions. The capsid peak fractions for GFP-R10 + AaLS-6D clearly show bands 
for both GFP-R10 and AaLS-6D. The GFP peak fractions show two bands as well. This 
pair of bands is probably a result of GFP-R10 interacting with the lesser oligomerized forms 
of AaLS-6D. These findings agree well with the fluorescence and UV absorption data to 
support the idea that there is a significant association between the deca-arginine tagged 













Figure 3.4. SDS-PAGE analysis of pooled SEC fractions from the capsid and GFP. Capsid 
(C) and GFP (G) peak fractions from the control and experimental mixes shown in Figure 
3.2 are labeled. Lane 1 contains the molecular weight ladder. The expected positions of 










3.2.5. Gel Mobility Shift Assay Shows a Band Present only in the 
GFP-R10 + AaLS-6D Mixture 
A native agarose gel shift mobility assay was performed with each GFP and AaLS 
variant run individually as well as in the three mixtures specified earlier. The individual 
GFP variants ran well and produced a single, well-defined band as viewed by both 
fluorescence and coomassie brilliant blue staining (Figure 3.5). The capsid variants also 
produced well-defined single bands. The mutant capsid appears to move further than the 
wild-type capsid, possibly due to the extra negative charge on the AaLS-6D variant (-25 
per pore, -300 per capsid).  
The GFP + AaLS-6D mixture behaved as expected with the individual components 
separating and moving exactly as their respective solo lanes did. The GFP-R10 + AaLS-WT 
mixture, however, showed a smeared fluorescence band which extended approximately 
half the length of the smear observed by staining with no clearly defined bands. This smear 
suggests weak interactions exist between AaLS-WT and GFP-R10 in the mobility shift 
assay running buffer that do not maintain cohesion under the higher ionic strength buffer 
conditions used during SEC. For comparison, the mobility shift assay running buffer has 
an ionic strength of 89 mM while the SEC running buffer varied in ionic strength from 
125 mM to 475 mM. These interactions may be occurring between the weakly anionic 
wild-type pore and the tag, but a visual inspection of the structure reveals eight negatively 
charged residues (three Asp, five Glu) per monomer on the exterior surface of the capsid. 
Thus, nonspecific interaction between the R10 tag and the outer capsid surface is another 
plausible explanation. The fact that the same fluorescent smearing is observed from the 









Figure 3.5. Native agarose gel mobility shift assay of the various GFP + capsid mixtures 
and their individual components. The positions of the individual proteins and the complex 




GFP-R10 + AaLS-6D lane also shows a clearly visible band at the end of the fluorescent 
smear. No other bands are present in the lane and this band is significantly shifted relative 
to both the GFP-R10 and AaLS-6D bands alone, indicating the cationic tag and anionic pore 
are able to interact with each other. 
3.2.6. Stoichiometry and Ionic Strength Dependence of the Tag-Pore Complex 
The architecture of the capsid gives rise to a single pore at the five-fold symmetry 
axis for a total of 12 pores per capsid. Therefore, we expected to see, at most, a ratio of 
twelve GFPs per capsid. However, at lower buffer ionic strengths, more than double that 
ratio was observed (Figure 3.6). The closest ratios to the expected 12:1 value were observed 
between ionic strengths of 225 mM to 275 mM. At higher buffer ionic strengths, the ratio 
dropped steeply until virtually no fluorescence was detected at 475 mM. 
Given that the interior surface of both the wild-type and mutant capsid has a mildly 
negative net charge (-1 per monomer, -60 per capsid), it is possible that the extra GFPs 
have been encapsulated. This possibility seems extremely unlikely as the capsid peak 
fraction from the GFP-R10 + AaLS-WT control did not exhibit any measurable 
fluorescence (Figure 3.2a). Additionally, previous work has shown that a larger AaLS 
variant with a significantly more negative interior surface only encapsulates three or four 
GFP-R10 molecules and that encapsulation of an R10 tagged guest does not occur when the 
components are mixed after individual purification.63 It is possible that more than one R10 
tag could be threading through the pore. However, this seems extremely unlikely as our 
calculations show there is only enough volume for a single tag. It may be possible, though, 













Figure 3.6. Ratio of GFP-R10 per capsid at various buffer ionic strengths. Complexes were 
isolated via SEC. AaLS-5D1N showed a decreased ratio compared to AaLS-6D at most 








In an effort to reduce the amount of nonspecific binding observed, a D108N 
mutation was introduced to AaLS-6D, creating AaLS-5D1N. By converting the aspartate 
to an asparagine, we hoped to abolish any binding occurring on the outer edge of the pore. 
This capsid variant retained the ability to bind the tagged GFP. The ratio of GFP:capsid 
did decrease at most ionic strengths; however, it also appears that the ionic strength at 
which a 12:1 ratio of GFP:capsid was reached dropped from 275 mM with AaLS-6D to 
225 mM with AaLS-5D1N (Figure 3.6). 
Regardless of how the tag(s) may be interacting with the pore, examination of the 
elution behavior of the GFP-R10 + AaLS-6D capsid on a SEC column using various ionic 
strengths of running buffer also suggests that the tagged GFP is decorating the surface of 
the capsid. Since SEC separates molecules by their hydrodynamic volume, if the bound 
GFP-R10's were being encapsulated, we would expect the capsid to elute at the same 
volume irrespective of the number of bound guests because there would be no expected 
change in the hydrodynamic volume of the complex in comparison to the capsid alone.  
What was actually observed was a slight but continual shift toward an earlier elution 
volume as the ionic strength of the running buffer was decreased (Figure 3.7). This shift is 
indicative of an increase in the hydrodynamic volume and is in keeping with what would 
be expected if the tag were binding to the pore with the guest on the outer surface of the 
capsid and an inverse relationship between the number of guest molecules and the ionic 
strength of the running buffer. This relationship is evinced by the increasing fluorescence 
intensity of the capsid peak as the ionic strength of the buffer decreases. It also supports 





Figure 3.7 Relative fluorescence of GFP-R10 + AaLS-5D1N complex and GFP-R10 SEC 
peaks at different buffer ionic strengths. The GFP- R10
 peak elutes later as the buffer ionic 
strength decreases due to increased interaction between the tag and the column matrix. 
Ionic strength was controlled via sodium chloride concentration and includes the 20 mM 





was no observed leveling off of the fluorescence intensity and earlier elution shifting of the 
capsid peak. 
3.2.7. KD Determination via Fluorescence Anisotropy 
Fluorescence anisotropy was used to determine the strength of the complex 
association. Briefly, a fluorophore excited by plane polarized light will fluoresce in the 
same plane. The faster the fluorophore rotates in solution, the lower the intensity of the 
polarized emissions. The magnitude of the intensity difference between a fluorophore free 
in solution and one bound to another molecule is called the fluorescence anisotropy. By 
measuring the observed anisotropy at a constant concentration of fluorophore in the 
presence of different concentrations of a molecule that binds to the fluorophore, it becomes 
possible to estimate the KD of the association.  
The results of several anisotropy experiments using either AaLS-6D or AaLS-
5D1N are shown in Figure 3.8. The estimated KD's for both are statistically identical, 
suggesting that the mutation converting the aspartate on the outer edge of the pore to an 
asparagine in AaLS-5D1N did not significantly affect binding of the tag to the pore. 
Further, the nanomolar concentration of the KD indicates an extremely strong affinity 
between the R10 tag and the negatively charged pore.  
3.2.8. Stoichiometry and KD Determination via Isothermal Titration  
Calorimetry 
In an effort to further corroborate these data, we collaborated with Stign von 











Figure 3.8. Affinity of GFP-R10 for AaLS variants. Fraction of GFP-R10 bound at various 
pore concentrations of AaLS-6D (A) or AaLS-5D1N (B) as determined by fluorescence 
anisotropy measurements. Experiments were conducted at room temperature with buffer 
ionic strength held constant at 275 mM. The [pores] is defined as the protein monomer 









measurements on the tag-pore complex (Figure 3.9).1 Initial calculations yielded an 
estimated KD of 114 nM and a GFP:capsid ratio of 6.7:1. However, our collaborators used 
spectroscopic methods to determine their protein concentrations. More specifically, they 
used A280 measurements with an extinction coefficient calculated via the ExPASy 
ProtParam tool to determine their capsid concentrations and A480 measurements with an 
empirically determined extinction coefficient to determine their GFP-R10 concentrations. 
This method results in capsid and GFP-R10 concentrations approximately 1.9 and 1.3 times 
higher, respectively, than the concentrations determined by Bradford assay, the method 
that we used exclusively for protein concentration determination. When the ITC 
measurements are adjusted for these differences, the GFP:capsid ratio becomes 13:1 and 
the calculated KD becomes 47 nM.  
Thermodynamic parameters derived from these data indicate approximate changes 
in enthalpy and entropy of -4.2 kcal/mol and 5.3 kcal/mol, respectively. These calculations 
suggest that the binding of the tag to the AaLS-5D1N pore is entropically driven, most 
likely by freeing water molecules bound to the interior of the otherwise empty pore. 
3.3. Discussion 
A variant of the AaLS capsid with a negatively super-charged five-fold axial pore 
and a GFP with a C-terminal deca-arginine tag were shown to form a novel association 
with each other via charge complementarity between the anionic pore and the cationic tag. 
This complex demonstrated strong binding with a KD in the low nanomolar range. Such an 
 
                                                          





















extremely tight binding affinity is on par with those determined for antibody-antigen 
interactions.186 
Antibodies often undergo a process called affinity maturation in which successive 
generations show stronger antigen affinities, usually by one or two orders of magnitude. 
Structural studies have shown that this improved affinity can be due to an increase in the 
rigidity and complementarity of the interface with a corresponding increase in the number 
of hydrogen bonds.187 This degree of interaction requires significant desolvation between 
the interfaces to prevent water from disrupting the hydrogen bonding network and salt 
bridges.  
Salt bridges are regularly found to be buried at protein-protein interfaces where 
they are often stabilizing and contribute significantly to the specificity of the interaction.188 
The strength of attraction between the two components, and therefore of the bridge itself, 
can be calculated from Coulomb's law which dictates that the strength increases as the 
dielectric constant of the environment decreases.189 The estimated packing efficiency of 
the tag-pore complex indicates a tight fit, very near the crystallographic maximum packing 
density. Given this projection, the fact that the association appears to be entropically 
driven, and arginine’s ability to form up to five hydrogen bonds, it seems likely that there 
will be little or no water in the interface, yielding an extensive network of high strength 
salt bridges and hydrogen bonds. 
Although it is strong, the association we generated is not highly specific. Any 
positively charged particle can associate with a negatively charged one. The architecture 
of the pore does impart some specificity as only molecules capable of fitting into the pore 




pore means a fairly wide variety of narrow, elongated molecules or small globular ones 
would be able to fit into the pore. This lack of specificity could be the source of the greater 
than 12:1 stoichiometries observed at low ionic strengths.  
It is also possible that the tag is only interacting with the surface of the pore, rather 
than threading through it as envisioned (Figure 3.10a). The hourglass shape of the pore 
causes it to flare wider at the ends, which could allow multiple tags to interact with just a 
few aspartates at the top of the pore. However, interacting like this would likely result in a 
significantly weaker dissociation constant than was observed. The fact that conversion of 
aspartate 108 to asparagine did not change the observed KD suggests that nonspecific 
interactions do not play a significant role in formation of the tag-pore complex at higher 
buffer ionic strengths.  
Alternatively, at lower ionic strengths, the R10 tag may be able to replace the 
positive residue in some or all of the 17 salt bridges found on the AaLS capsid surface. The 
smeared fluorescence seen in the gel mobility shift assay (Figure 3.5 lane 6) indicates some 
degree of association between GFP-R10 and the wild-type capsid. However, at the higher 
ionic strength of the SEC running buffer, there is no sign of any interaction between the 
two (Figure 3.2a). This supports the idea that there is some degree of nonspecific 
interaction between the R10 tag and the surface of the capsid in low ionic strength buffer. 
The sensitivity of the complex to ionic strength indicates that the association should 
be tunable based on the buffer conditions and the amino acid content of the tag and pore. 
Fewer positive and/or negative charges should result in a weaker complex which 
dissociates at an ionic strength lower than 375 mM, as we observed. Given the fact that the 













Figure 3.10. Potential binding modes between the deca-arginine tag and the pore. A) 
Threaded through the pore as envisioned. B) Interacting only with the surface aspartates of 










amount (150 mM vs 250 mM, respectively), this enhances the potential use of the capsid 
as a drug delivery vehicle. 
It may be possible to reduce the strength of the tag pore complex via mutagenesis 
such that transition from the blood to the cell interior causes the complex to dissociate, 
thereby exposing the interior of the capsid and allowing delivery of small molecule drugs. 
Further, the multivalent display of receptor binding proteins to address the capsid to 
specific cell types would be easily achievable by appending the tag to these proteins. Thus, 
the problems of specific delivery and drug release may both potentially be addressed via a 
single, novel protein-protein interface. 
In addition, control over supramolecular assembly and multivalent display is a 
highly desirable trait for such nanotechnology applications as antigen display in vaccines, 
control over nanoreactor activity, and production of novel nanoscale architectures. Our 
method of functionalizing the AaLS capsid pore surface is compatible with previously 
reported surface engineering techniques such that the simultaneous multivalent display of 
several different guest proteins may be possible. The use of a charge 
complementarity-based tagging system to functionalize capsid pores should be generally 
applicable to other capsids or tunnel bearing structures as a means of engineering novel 
supramolecular assemblies. 
3.4. Materials and Methods 
3.4.1. Materials 
All cell culture media and chemical reagents were purchased from Bio-rad, Fisher 




purification. BL21 (DE3) and XL1-Blue E. coli cell strains and Pfu-turbo DNA polymerase 
were purchased from Stratagene. T4 DNA ligase and all restriction endonucleases were 
purchased from New England Biolabs. The oligonucleotides used in this study were 
synthesized by the DNA/peptide synthesis Core Facility at the University of Utah. 
3.4.2. Mutagenesis 
In order to make AaLS-6D, site-directed mutagenesis PCR was carried out using 
pMG-AaLS as the template plasmid for the mutagenic primers EH10 and EH11 (Table 
3.1). A 51 µL reaction volume was made by mixing the following: nanopure water (42 µL), 
10x reaction buffer (5 µL), 10 ng/µL template DNA (1 µL), 250 ng/µL forward and reverse 
primers (0.5 µL each), dNTP mix (1 µL), and 2.5 U/µL Pfu-turbo DNA polymerase (1 µL). 
The reaction was carried out using a Mastercycler Personal Thermocycler (Eppendorf). 
The polymerase was activated (95 °C for 30 seconds) prior to initiation of the mutagenesis 
reaction which was carried out for 18 cycles of denaturation (95 °C for 30 seconds), 
annealing (55 °C for 1 minute), and primer extension (68 °C for 12 minutes). The mixture 
was then cooled to 37 °C and incubated for 1 hour with 1 µL DpnI (10 U/µL) to remove 
the template plasmid.  
The product plasmid was transformed via heat shock (42 °C for 1 minute) into 
CaCl2 competent XL1-Blue cells. These cells were then grown on 100 µg/mL AMP LB-
agar plates overnight at 37 °C. Colonies were selected, grown in 6 mL LB media containing 
AMP, and plasmid DNA extracted via a QIAprep Spin Miniprep Kit (Qiagen) as per the 
manufacturer's protocol. The presence of the desired mutations was confirmed by DNA 











Table 3.1 List of mutagenic primers used to generate the capsid variant, AaLS-5D1N. 
Mutagenic bases are bolded. 
 
















protocol to the one described above was used to produce pMG-AaLS-5D1N from 
pMG-AaLS-6D and the primers AaLS-KINGf and AaLS-KINGr.  
3.4.3. Production and Purification of Crude Protein 
All proteins were produced in CaCl2-competent BL21 (DE3) E. coli cells. 
Transformation of the gene-bearing plasmids (pMG-AaLS (hexahistidine tagged wild-type 
capsid), pMG-AaLS-6D, pMG-AaLS-5D1N, pACYC-GFP, or pACYC-GFP-R10) was 
accomplished via heat shock at 42 °C for 2 minutes. The cells were then grown at 37 °C 
for 1 hour and plated on antibiotic-containing LB agar plates (50 µg/mL chloramphenicol 
(CAM) for pACYC plasmids, 100 µg/mL ampicillin (AMP) for pMG plasmids). The plates 
were grown overnight in a 37 °C oven. A single colony was selected from the plate and 
used to inoculate a 7.5 mL antibiotic-containing LB culture which was then grown 
overnight at 37 °C with shaking at 250 rpm. An aliquot of this culture (1 mL) was then 
used to inoculate antibiotic-containing LB media (500 mL). Over-production of the desired 
protein was achieved by growing this large culture at 37 °C to an OD600 of 0.7, inducing 
production by adding IPTG to a final concentration of 0.2 mM, and then incubating the 
cultures at 30 °C for 20 hours at 250 rpm. The cells were harvested via centrifugation in a 
Sorvall RC 6+ centrifuge with a Fiberlite F10 6x500y rotor (6000 rpm for 15 minutes at 
4 °C). Pellets were frozen at -80 °C until used.  
Cell pellets were resuspended in 10 mL of lysis buffer (50 mM sodium phosphate, 
300 mM NaCl, pH 8.0). The cells were lysed by incubation with lysozyme (10 mg), RNase 
A (1.2 mg), and DNase I (20 µg) on ice for 1 hour followed by sonication at 45 µm 




processor. The lysate was then clarified by centrifugation in a Sorvall RC 6+ centrifuge 
with a Fiberlite F10 6x500y rotor (12000 rpm for 45 minutes at 4 °C). Unless stated 
otherwise, a Bradford assay was used to determine all protein concentrations. 
3.4.4. Purification of AaLS Capsid Variants 
For purification of AaLS-WT, AaLS-6D, or AaLS-5D1N, the supernatant was 
loaded onto a Ni2+-NTA resin which had been equilibrated with lysis buffer and incubated 
for 1 hour at 4 °C with gentle rocking. The column was then washed with lysis buffer, lysis 
buffer containing 40 mM imidazole, and lysis buffer containing 500 mM imidazole. The 
high imidazole fraction was then concentrated. The assembled capsid was isolated by 
loading the sample onto an ÄKTA FPLC system (GE Healthcare) equipped with a HiPrep 
16/60 Sephacryl S-400HR column and run with tris running buffer (20 mM Tris, 500 mM 
NaCl, 5 mM EDTA, pH 8 ) at 4 °C at a flow rate of 0.5 mL/min. 
3.4.5. Purification of GFP Variants 
Prior to dialysis, all GFP and GFP-R10 samples were treated with saturated 
ammonium sulfate in lysis buffer to a final concentration of 40% v/v ammonium sulfate. 
These samples were incubated at room temperature for 1 hour and then clarified by 
centrifugation in a Sorvall RC 6+ centrifuge with a Fiberlite F10 6x500y rotor (10,000 rpm 
for 15 minutes at 4 °C). The supernatant was retained and the target protein was further 
purified from the crude sample as described in section 2.4.4. The untagged GFP variant 
was loaded onto a MonoQ 5/50 GL column while GFP-R10 was loaded onto a MonoS 5/50 




gradient ranging from 0% to 100% ion exchange buffer B run at 4 °C. Fractions that 
fluoresced green to the naked eye were pooled and then loaded onto a HiLoad 16/60 
Superdex 75 PG column run with tris running buffer at 4 °C. 
3.4.6. Assembly and Isolation of the Tag-Pore Complex 
Mixtures of GFP and capsid were prepared in tris running buffer by combining a 
GFP variant with a capsid variant to final concentrations of 1 mg/mL and 0.5 mg/mL, 
respectively. This results in a 72-fold molar excess of GFP (6-fold compared to the pores). 
The components were added in the following order: tris running buffer, GFP, capsid. The 
sample was produced in a 2.5 mL volume and dialyzed overnight at 4 °C, with gentle 
stirring, into working buffer (identical to tris running buffer but with the [NaCl] varying 
from 100 mM to 450 mM) of the desired ionic strength. The ionic strength of the buffer 
was controlled by manipulating the concentration of NaCl. The sample was then loaded 
onto an ÄKTA FPLC system (GE Healthcare) equipped with a HiPrep 16/60 Sephacryl S-
400HR column and run with the same ionic strength tris buffer that the sample was 
previously dialyzed into. Fluorescence measurements were taken for all fractions eluted 
from the column. 
3.4.7. Native Agarose Gel Mobility Shift Assay 
A 2% w/v agarose gel was prepared using running buffer consisting of 89 mM Tris, 
89 mM Boric acid, at pH 8.4. The sample loading buffer consisted of running buffer, 3 mM 
bromophenol blue, and 20% v/v glycerol. Samples were prepared by combining a 10 µL 




preparation was loaded into a single well on the gel which was run at 100 V for 70 minutes. 
Gels were cast and run in a Bio Rad Mini-Sub Cell GT using a Bio Rad PowerPac Basic. 
All gels were initially visualized via UV-induced fluorescence on a UVP Benchtop 
Transilluminator to locate GFP in the samples. They were then stained overnight with 
Coomassie Brilliant Blue to locate all proteins in each sample. 
3.4.8. Fluorescence Measurements 
All fluorescence and fluorescence anisotropy measurements were conducted on a 
Hitachi F-7000 Fluorescence Spectrophotometer with the sensitivity set to 450 V. The 
polarizer attachment was used for all fluorescence anisotropy measurements. Fluorescence 
anisotropy measurements were carried out in 20 mM Tris, 250 mM NaCl, 5 mM EDTA, 
pH 8 buffer. Samples were prepared immediately prior to analysis and allowed to 
equilibrate for 15 minutes at room temperature, in the dark. The initial sample consisted of 
20 nM GFP-R10 and 5 µM AaLS pores (0.4 µM capsid) in a total volume of 2 mL. The 
fluorescence anisotropy of this sample was measured and the concentration of AaLS pores 
was then diluted by removing 1 mL of the sample and replacing it with 1 mL of a 20 nM 
GFP-R10 solution in the same buffer. This cycle of measurement and dilution was repeated 
ten more times. Data were fit to Equation 3.1 with the following parameters: B is the 
fraction of bound ligand, LT is the total concentration of ligand, RT is the total concentration 
of receptor (AaLS capsid pores), and KD is the dissociation constant. The fraction bound 
was estimated as the measured anisotropy over the maximum observed anisotropy. 
B = [LT + KD + RT - ([LT + KD + RT]
2 - 4LT RT)




3.4.9. Isothermal Titration Calorimetry 
All ITC experiments were carried out using a Microcal Auto-iTC200 (GE 
Healthcare). Samples were analyzed in 20 mM Tris, 250 mM NaCl, 5 mM EDTA, pH 8 
buffer at 25 °C. A 400 µL aliquot of 57 µM 5D1N monomer was titrated via 19 injections 
(2 µL each) of 93 µM GFP-R10. Results were analyzed using Origin 6.0 (Microcal) and 
fitted using a nonlinear single site binding model. The concentrations of all proteins used 
for ITC measurements were determined spectrophotometrically as discussed in section 
3.2.8. 
3.4.10 Transmission Electron Microscopy 
In order to visualize the mutant capsid alone and in complex with GFP-R10, 10 µL 
of the each sample was applied to separate 200 square mesh, formvar coated copper grids. 
Samples were allowed to adhere to the grid for 1 minute before the excess was wicked 
away with sterile filter paper. The grids were then stained for 1 minute using 2% 
phosphotungstic acid (pH 8.0). Excess stain was wicked away with sterile filter paper. 
Sample images were obtained on a Hitachi 125 keV H-7100 Transmission Electron 
Microscope equipped with a Gatan Orius SC1000 slow scan 4kX2.6k CCD camera and 
analyzed using ImageJ software (National Institutes of Health). 
  
CHAPTER 4 
FURTHER EXPLORATION OF AN ENGINEERED REDOX SWITCH AND 














Polyhedral capsids represent one of the more common multimeric protein 
associations. The building blocks of such structures typically self-assemble in a 
hierarchical fashion to form symmetric, hollow shells that can serve as molecular 
containers.11,21 The functions of protein capsids include protection of encapsulated guest 
molecules, sequestration of toxins, and enhancing the speed and efficiency of metabolic 
pathways. Thus, there has been significant interest in harnessing these structures for use in 
nanotechnology. In particular, control over capsid assembly and disassembly is highly 
desirable as it allows for precise loading and unloading of guest molecules. 
The capsid formed by Aquifex aeolicus lumazine synthase (AaLS) provides an 
attractive platform for nanotechnology. AaLS forms a dodecahedral capsid from 60 
identical subunits, which can be viewed as a dodecamer of pentamers.131 Previously, our 
lab reported the generation of a pentameric variant of AaLS (AaLS-Switch-Red), which 
contains point mutations near the two-fold (R40S and H41S) and three-fold (I125C) 
symmetry axes of the wild-type capsid.135 The mutations along the two-fold axis disrupt a 
hydrogen bonding network while the mutation at the three-fold axis replaces a hotspot 
residue within a hydrophobic cluster. These regions are part of the pentamer-pentamer 
interface within the capsid. The aforementioned mutations disrupt the noncovalent 
interactions which stabilize this interface, resulting in the formation of individual 
pentamers rather than full capsids. 
AaLS-Switch-Red can be induced to form wild-type-like capsids via disulfide bond  
formation between the engineered cysteine (at position 125) and thiophenol (Figure 4.1) to 










Figure 4.1. General schematic of the thiol disulfide exchange reaction used to induce capsid 
assembly. First, the engineered cysteines (orange) on each pentamer were primed by 
reaction with DTNB to form the AaLS-Switch-NTB adduct (top right). Next, the NTB 
moiety was replaced with one of the thiols shown in Table 4.1, denoted as R, and the 








this modification presumably allows for the reconstitution of the hydrophobic cluster at the 
three-fold symmetry axis and drives capsid assembly by AaLS-Switch-Ox.  
Here, we expand upon this work by examining how capsid assembly is affected by 
the size and shape of the thiol adduct. Interestingly, we find that capsid assembly by 
AaLS-Switch-Ox can tolerate a wide range of aliphatic and aromatic prosthetic groups, 
suggesting that this hot spot in the pentamer-pentamer interface of the capsid is quite 
plastic. In addition, we use this disulfide exchange system as a means of combining both 
pH and redox sensitive switches for further control over capsid assembly and disassembly. 
4.2. Results 
4.2.1. Formation of the Pentamer-Thiol Adducts 
Formation of the pentamer-thiol adducts was accomplished via a two-step disulfide 
exchange reaction in which the Switch-Red pentamer was initially treated with DTNB to 
generate an adduct via disulfide bond formation between cysteine 125 of each monomer 
and NTB (Switch-NTB). This initial adduct formation was typically accomplished with 
greater than 90% efficiency. The Switch-NTB adduct was then reacted with the desired 
thiol to form the final Switch-Thiol adduct via displacement of the NTB moiety by the 
added thiol. Reaction efficiency was monitored via UV-spectroscopy by measuring the 
absorbance of the solution at 412 nm. The majority of these disulfide exchange reactions 
showed greater than 80% efficiency (Table 4.1).  
Mass spectrometry was used to confirm the presence of the intended adduct (Table 
4.2). The spectra for all tested samples showed a peak corresponding to the expected size 






Table 4.1 Formation efficiency and capsid yield of the various capsid generating adducts. 
Overall capsid yield was calculated by dividing the mass of protein obtained from the SEC 
capsid elution peak by 4 mg of starting material. Adjusted capsid yield was calculated by 














Table 4.2 Mass spectrometry results for the different AaLS-Switch variants. 
AaLS-Switch Variant Calculated Mass (Da) Observed Mass (Da) 
Red 16786 16787 
NTB 16985 16983 
n-Butyl 16874 16880 
t-Butyl 16874 n.d. 
Pent 16888 16889 
TMP 16931 16855 
Hex 16902 16899 
CHex 16900 16899 
Hep 16917 16919 
Oct 16931 16998 
Ox 16894 16898 
mOx 16908 16910 
eOx 16922 16926 
2TP 16895 16881 
4TP 16895 16898 
Bz 16876 16878 
Bz† 16924 16925 
† AaLS-Switch-Bz after 24 hour peroxide treatment. The calculated mass assumed that all 







a spectrum with many peaks, including a major peak corresponding to the expected mass 
plus 67 Da. This additional mass is very close to the expected mass of three sodium atoms 
and is likely due to residual salt that was not properly cleared from the sample. The major 
peaks for the Switch-TMP and Switch-2TP samples were 76 and 14 Da lower than 
anticipated, respectively. It is not immediately clear what these peaks indicate about their 
respective samples as the missing masses do not correspond to any probable adduct 
fragments.  
4.2.2. Verification of Assembly of Pentamer-Thiol Adducts into Capsids 
After thiol treatment, the resulting adducts were dialyzed to remove excess thiol 
reagent and assembled via incubation with PEG-3350 for two days. The procedure used in 
this study was a scale-up of the previously reported assembly method using Switch-Ox85. 
The original protocol called for a 1 mL reaction volume and gave quantitative assembly 
after two days while the protocol reported here employed a 4 mL reaction volume and did 
not achieve quantitative assembly for any of the tested thiol adducts. The reason for this 
nonlinear behavior is not immediately apparent. Assembled capsids were separated from 
lower order aggregates and unassembled pentamers via SEC (Figure 4.2). Fully formed 
capsids typically eluted at 69-70 mL (Table 4.3). None of the thiols shorter than four 
carbons in length assembled into capsids (Figure 4.2 c,d,e).  
TEM images of the capsid elution peaks were obtained to visually verify that they 
had assembled into capsids and to determine their sizes (Figure 4.3). The assembled 







Figure 4.2. SEC chromatograms of all tested thiol assemblies. AaLS-WT and 
AaLS-Switch-red are shown as capsid and pentamer references, respectively. Data for the 
latter was collected by H. Chen. Expected elution volumes are denoted for capsid (green) 


























Table 4.3 Size analysis of the different thiol capsids. 










n-Butyl 69 14 ± 2 168 
t-Butyl 69 n.d. - 
Pent 69 16 ± 2 183 
TMP 68 15 ± 2 125 
Hex 69 16 ± 1 151 
Chex 70 14 ± 2 87 
Hep 70 13 ± 1 116 
Oct 70 15 ± 2 107 
Ox 69 16 ± 2 77 
mOx 70 15 ± 2 71 
eOx 73 14 ± 1 134 
2TP 70 16 ± 2 199 
4TP 69 18 ± 2 347 





















spectrometry was used to confirm the existence of the thiol adduct in samples showing 
capsid assembly (Table 4.2). 
4.2.3. Attempted Disassembly of the Switch-Thiol Capsids via DTT Treatment 
In an effort to generate a redox controlled assembly, several attempts were made to 
induce dissociation of the capsids back into pentamers via treatment with the reducing 
agent DTT. None of the capsids so treated showed quantitative dissociation of the capsid 
to pentamers in phosphate buffer (Figure 4.4). Several of the capsids showed minimal 
amounts of disassembly (Figure 4.4 c, d, e, i, j), but only the Switch-t-Butyl and 
Switch-eOx capsids showed significant conversion to pentamer when exposed to DTT in 
phosphate buffer (Figure 4.4 b, k). Dialysis of the thiophenol capsid into nanopure water 
followed by treatment with 10 mM DTT for 24 hours and subsequent dialysis back into 
phosphate buffer resulted in the complete disassembly of the capsid to pentamers (Figure 
4.5). The nature of this disassembly suggests that the phosphate buffer may be interfering 
with the ability of DTT to free the thiol adduct. Therefore, we dialyzed various thiol capsids 
into citrate buffer (Figure 4.6) and attempted to once again disassemble them using DTT.  
Upon initial dialysis into citrate buffer, both Switch-eOx and -2TP showed a 
broadened and delayed capsid peak suggesting an assembly state somewhere between 
pentamer and capsid (Figure 4.6 k, l). Surprisingly, Switch-TMP appeared to completely 
disassemble into pentamers (Figure 4.6 d). The pentamers elute at a significantly later 
volume in citrate buffer (110 mL) than they do in phosphate buffer (90 mL). DTT treatment 





Figure 4.4 SEC chromatograms of capsid samples treated with DTT in phosphate buffer. 




















Figure 4.5 Size analysis of DTT treated Switch-Ox. Switch-Ox capsid was either treated 
with DTT in phosphate buffer (black) or dialyzed into water, treated with DTT, then 
dialyzed back into phosphate buffer (red). Expected elution volumes are denoted for capsid 













Figure 4.6. SEC chromatograms of capsid samples dialyzed into citrate buffer. AaLS-WT 
and AaLS-Switch-pH are shown as capsid and pentamer representatives, respectively. 
Switch-pH data collected by H. Chen. Expected elution volumes are denoted for capsid 












4.2.4 Development of a pH Inducible Disassembly Switch 
Previous work has demonstrated that mutation of three residues at the three-fold 
symmetry axis to histidines (T120H, E122H, and Q123H), in addition to two mutations 
which destabilize the pentamer interfaces at the two-fold symmetry axis (R40S and H41S), 
results in a variant of AaLS which assembles into a capsid at pH 8 but reversibly 
disassembles to pentamers when the pH is lowered (AaLS-Switch-pH).85 We attempted to 
mimic this approach by covalently bonding either 2- or 4-thiopyridine (2TP and 4TP, 
respectively) to the C125 residue. Thiopyridines were chosen for their structural similarity 
to thiophenol and their pKa values. Formation of the 4TP adduct was the least efficient of 
all tested thiols followed by Switch-2TP. The thiopyridines also had the lowest yield of 
fully formed capsid.  
4.2.5 Attempted Design of an Oxidative Switch for Capsid Disassembly 
In an effort to make a redox switch which remains conjugated to the AaLS-Switch 
protein in both the pentameric and full capsid forms, a benzyl group was conjugated to 
C125 using benzyl bromide as the starting reagent. Since the benzyl group does not contain 
a sulfur atom, it is incapable of forming a disulfide bond. Instead, a bromine radical leaves 
which forms a benzyl radical that then attacks the cysteine thiol to form a thioether. This 
thioether may be reversibly oxidized to a sulfoxide. It was hoped that the steric repulsion 
caused by the addition of an oxygen to the thioether would be sufficient to induce 




The Switch-Bz adduct assembles into capsid like the majority of the tested thiols. 
The thioether was oxidized to a sulfoxide using hydrogen peroxide (H2O2). After a 24-hour 
treatment with H2O2, the sample and untreated control were analyzed via SEC (Figure 4.7). 
The traces for each were identical, showing no dissociation of the capsid due to H2O2 
exposure.  
Mass spectrometry analysis exhibited a large peak corresponding to the size 
expected if the two endogenous methionine sidechains and the cysteine adduct were 
oxidized to sulfoxides, demonstrating that the intended reaction did take place (Table 4.3). 
However, the second largest peak, corresponding to the mass of the unmodified Switch-Bz 
adduct, had an intensity of roughly half that of the major peak, suggesting that a significant 
amount of the available protein did not react. Interestingly, there were no peaks 
corresponding to the sizes expected for the reaction of only one or two of the available 
sulfides. 
4.3. Discussion 
A minimum adduct size of five nonhydrogen atoms (one sulfur and four carbons) 
were found to be necessary in order to induce capsid assembly. The reduced or NTB-adduct 
forms of the protein show no higher order structures beyond pentamers while conjugation 
to two or three carbon thiols resulted in a mixture of pentamers, intermediate aggregation 
states, and over-assembled aggregations. Use of linear thiol adducts ranging from four to 
eight carbons in length, two different branched chain thiols, or cyclic thiols containing six 
or more carbons all yielded capsids in similar sizes, suggesting that the three-fold 












Figure 4.7. SEC chromatogram of untreated Switch-Bz capsid and the same capsid treated 
with hydrogen peroxide for 24 hours. Analysis by mass spectrometry indicates that the 











In general, as the formation efficiency of the Switch-adduct complex increased, so 
did the capsid yield (Figure 4.8 b, d). At the highest levels of efficiency, there should be a 
greater number of pentamers in which all five cysteines have been modified and thus fewer 
assembly dead ends, which will translate into a higher yield of capsid. Linear regression 
suggests that the minimum adduct yield must be greater than 37% in order to form capsid 
(Figure 4.8 b). This corresponds to an average of 1.9 modified cysteines per pentamer. 
However, given the extremely low amounts of capsid obtained for adduct formation yields 
of less than 70% (an average of 3.5 modified cysteines per pentamer), this value may be a 
more realistic minimum. Precipitation was frequently observed during adduct formation. 
This loss of product could be exacerbating the uncertainty in this estimate by artificially 
deflating the minimum adduct yield. No clear trends emerged when examining adduct or 
capsid yields as a function of adduct molar mass (Figure 4.8 a, c, e).  
In addition to improving our understanding of how the structure of the hydrophobic 
adduct influences capsid assembly, we also attempted to produce both a redox and a pH 
switch for control over said assembly. In pursuit of this goal, the various capsids were 
treated with DTT to see if it would be able to free the thiol adducts and thereby induce 
disassembly of the capsid. Unfortunately, this approach was not successful. However, the 
fact that small amounts of pentamer were observed for several of the treated capsids 
coupled with the fact that the thiophenol capsid was successfully disassembled in nanopure 
water with DTT means further study with varying combinations of reducing agents and 








Figure 4.8. Analysis of adduct and capsid yields. No strong trends are evident when 
examining adduct or capsid yield as a function of adduct mass. A weak correlation between 






H2O2 to oxidize the thioether bond in the Switch-Bz variant, was unsuccessful and the 
evidence does not suggest that this approach is worth pursuing further. 
Attempts to engineer a pH switch for control of capsid assembly using thiopyridines 
were also unsuccessful. However, the Switch-2TP capsid did exhibit unusual behavior in 
that it appears to partially disassemble in pH 5.7 citrate buffer. This may be useful if these 
lower order aggregates allow access to the capsid interior and/or dialysis back into 
phosphate buffer causes the capsid to reassemble. Alternatively, it is possible that the 
capsid has contracted in diameter without disassembling. Changes in capsid size based on 
pH have previously been observed in viral capsids and BsLS but not AaLS-WT.190,191 
Switch-eOx exhibited similar behavior to Switch-2TP so it may also be a potentially pH 
switchable capsid.  
Finally, we found that the Switch-TMP capsid completely dissociated into 
pentamers upon dialysis into citrate buffer at pH 5.7. AaLS-Switch-pH has previously been 
shown to dissociate into pentamers reversibly, suggesting that the Switch-TMP pentamers 
may be able to reform capsid as well. In addition to pH, the identity of the buffer appears 
to play a role in the assembly state of the thiol-modified AaLS-Switch protein. Thus, 
exploring different buffers may lead to new redox- and pH-based assembly switches.  
The work reported here expands our understanding of how to reengineer protein 
interfaces for controllable supramolecular assembly. The ability to efficiently pack a 
diverse set of hydrophobic sidechains, as demonstrated by the variety of thiol adducts 
which assemble into capsid, indicates the AaLS three-fold axis is a highly plastic interface 
capable of adjusting to significant alteration. This adaptability is further evinced by our 




potential shown by several of the other variants. Additionally, our methods may serve as a 
generally applicable means of engineering assembly switches into other capsids with robust 
interfaces.  
4.4. Materials and Methods 
4.4.1. Materials 
All cell culture media and chemical reagents were purchased from Bio-rad, Fisher 
Scientific, Gold Biotechnology, or Pierce Biotechnology and used without further 
purification. BL21 (DE3) and XL1-Blue E. coli cell strains and Pfu-turbo DNA polymerase 
were purchased from Stratagene. DTT was purchased from Research Products 
International. Butanethiol was purchased from Acros. All other thiol reagents where 
purchased from Sigma-Aldrich. All thiol reagents were used without further purification. 
4.4.2. Production and Purification of AaLS-Switch-Red 
Protein was produced in CaCl2-competent BL21 (DE3) E. coli cells. 
Transformation of the gene-bearing plasmid (pMG-AaLSNoHis-switch-red85) was 
accomplished via heat shock at 42 °C for 2 minutes. The cells were then grown at 37 °C 
for 1 hour and plated on antibiotic-containing LB agar plates (100 µg/mL ampicillin). The 
plates were grown overnight in a 37 °C oven. A single colony was selected from the plate 
and used to inoculate a 7.5 mL AMP-containing LB culture which was then grown 
overnight at 37 °C with shaking at 250 rpm. An aliquot of this culture (1 mL) was then 
used to inoculate AMP-containing LB media (500 mL). Over-production was achieved by 




to a final concentration of 0.2 mM, and then incubating the culture at 30 °C for 20 hours at 
250 rpm. The cells were harvested via centrifugation in a Sorvall RC 6+ centrifuge with a 
Fiberlite F10 6x500y rotor (6000 rpm for 15 minutes at 4 °C). Pellets were frozen at -80 °C 
until used. 
Cell pellets were resuspended in 10 mL of lysis buffer (50 mM sodium phosphate, 
300 mM NaCl, pH 8.0). The cells were lysed by incubation with lysozyme (10 mg), RNase 
A (1.2 mg), and DNase I (20 µg) on ice for 1 hour followed by sonication at 45 µm 
amplitude for 3 minutes in 10 second on/off pulses using a Misonix ultrasonic liquid 
processor. The lysate was then clarified by centrifugation in a Sorvall RC 6+ centrifuge 
with a Fiberlite F10 6x500y rotor (12000 rpm for 45 minutes at 4 °C). 
AaLS-Switch-Red was purified from the crude protein sample as previously 
described85. Briefly, the supernatant was heated for 5 minutes in a water bath at 60 C. The 
heated sample was then centrifuged in a Sorvall RC 6+ centrifuge with a Fiberlite F10 
6x500y rotor at 12,000 rpm for 45 minutes at 4 °C. This supernatant was then dialyzed 
overnight into ion exchange buffer A at 4 °C. The freshly dialyzed sample was then loaded 
onto the FPLC equipped with an anion-exchange MonoQ 5/50 GL column which had been 
equilibrated with ion exchange buffer A. Bound protein was eluted using a gradient ranging 
from 0% to 100% ion exchange buffer B run at 4 °C. The flow-through fractions were then 
pooled and reinjected on the MonoQ column. The same gradient as the initial injection was 
used for elution. SDS-PAGE with a Thermo Scientific Unstained Molecular Weight 
Marker was then used to determine which fractions contained the pentamer. These fractions 
were pooled, concentrated, and then loaded onto a HiPrep 16/60 Sephacryl S-300HR 




4.4.3. Preparation of AaLS-Switch-NTB from AaLS-Switch-Red 
Purified AaLS-Switch-Red was concentrated to approximately 1 mg/mL in lysis 
buffer B (50 mM sodium phosphate, 200 mM NaCl, pH 8.0) and divided into five equal 
aliquots (typically 1-5 mL). The volume of a 20 mM 5,5'-dithiobis-(2-nitrobenzoate) 
(DTNB) solution in lysis buffer B needed to achieve a final concentration of 600 µM 
DTNB was calculated and divided into five even aliquots. One aliquot of the protein 
solution was dripped into one aliquot of the DTNB solution at a rate of approximately one 
drop/s with gentle stirring. This process was repeated for the other four aliquots of each 
solution and then all five were allowed to stir in the dark at room temperature for 1 hour. 
In order to remove excess DTNB, the aliquots were pooled and dialyzed into ion exchange 
buffer A over the course of three days with the buffer being refreshed once per day. After 
dialysis, the protein concentration was measured by Bradford assay. 
4.4.4. Assessment of the Efficacy of NTB Conjugation 
Ideally, since there is a single cysteine per monomer, treatment of 
AaLS-Switch-Red with DTNB should result in the quantitative formation of an 
AaLS-Switch-Red-2-nitro-5-thiobenzoate adduct (AaLS-Switch-NTB). NTB can be 
cleaved from the AaLS-Switch-NTB via treatment with dithiothreitol (DTT) and free NTB 
has an extinction coefficient of 14,150 M-1cm-1 at 412 nm; therefore, it is possible to 
colorimetrically assess the degree of NTBylation of AaLS-Switch-NTB. 
An aliquot of 99 µL of AaLS-Switch-NTB solution was combined with 1 µL of 
1 M DTT and allowed to equilibrate for 1 hour at room temperature. The absorbance at 




free NTB in solution. Typical batches gave a ratio of mol NTB per mol protein of 
0.97 ± 1.1, indicating nearly quantitative yields of adduct formation. 
4.4.5. Production of Other Thiol Adducts from AaLS-Switch-NTB 
A disulfide exchange reaction was conducted in order to replace NTB with another 
thiol. A 10-fold excess of the thiol replacement was added to 4 mL of 1 mg/mL 
AaLS-Switch-NTB and incubated at room temperature with gentle stirring for 1 hour. 
Typically, the solution turned bright yellow immediately upon thiol addition. An 
assessment of the efficiency of NTB replacement was made by measuring the absorbance 
of the reaction mixture at 412 nm and calculating the moles of NTB freed per mole of 
monomer. The sample was then dialyzed into ion exchange buffer A to remove excess 
unreacted thiol and free NTB. Typical capsid yield was approximately 35% or 1.4 mg of 
protein from a standard starting batch of 4 mL of 1 mg/mL Switch-NTB (Table 4.1).  
4.4.6. Assembly of AaLS-Switch-Thiol Capsids and SEC Analysis 
of Assembly State 
Upon removal from dialysis, the AaLS-Switch-Thiol samples were treated with 
25% w/v PEG-3350 in lysis buffer B to a final PEG percentage of 10%. The mixture was 
then allowed to stir gently at room temperature, in the dark, for two days. At the end of this 
incubation, it was very common to see a small amount of fluffy, white precipitate present 
in the reaction mixture. The sample was then filtered over a 0.2 µm Whatman Puradisc 
filter and loaded into a 30 kDa MWCO Vivaspin concentrator. Removal of PEG-3350 from 




a Fiberlite F10 6x500y rotor at 8,220 rpm for 10-20 minutes at 4 °C followed by dilution 
with buffer lacking PEG-3350. This cycle of concentration and dilution was maintained 
until the estimated remaining percentage of PEG-3350 was less than 0.01%. Higher 
concentrations of PEG-3350 (0.1-1%) were found to give anomalous SEC traces. Final 
volumes were typically 1 – 4 mL.  
The assembly states of the various AaLS-Switch-Thiol samples were assessed 
using a HiPrep 16/60 Sephacryl S-400HR column injected with 1-4 mL of sample and run 
with lysis buffer B at 4 °C. Elution volumes of the samples were compared to the volumes 
of the AaLS-WT capsid and a pentameric variant, AaLS-R40S/H41S/I125S.  
4.4.7. Transmission Electron Microscopy 
In order to visualize the assembled capsid, 10 µL of the various AaLS-Switch-Thiol 
samples were applied to 200 square mesh, formvar coated copper grids. Samples were 
allowed to adhere to the grid for 1 minute before the excess was wicked away with sterile 
filter paper. The grids were then stained for 1 minute using 2% phosphotungstic acid (pH 
8.0). Excess stain was wicked away with sterile filter paper. Sample images were obtained 
on a Hitachi 125 keV H-7100 Transmission Electron Microscope equipped with a Gatan 
Orius SC1000 slow scan 4kX2.6k CCD camera and analyzed using ImageJ software 
(National Institutes of Health).  
4.4.8. Disassembly of AaLS-Switch-Thiol Adducts 
In an effort to disassemble the AaLS-Switch-Thiol capsids, 1 mg/mL samples in 




state of these capsids after DTT treatment was assessed as described in section 4.4.6. 
Attempts to disassemble the capsid by altering the buffer composition and pH were also 
conducted. A phosphate buffer was not used for low pH applications because the AaLS 
capsid has been shown to precipitate in phosphate buffer at a pH lower than 6. 
Samples were dialyzed into citrate buffer (50 mM sodium citrate, 200 mM NaCl, 
pH 5.7) and their assembly state analyzed as described in section 4.4.7. Those still 
determined to be capsid where then treated with DTT as described above and their 
assembly state analyzed as described in section 4.4.6.  
4.4.9. Formation of the AaLS-Switch-Bz Capsid 
Since AaLS-Switch-Bz was to be formed via attack of the cysteine thiol on benzyl 
bromide, AaLS-Switch-NTB would not have been a productive starting reagent. Thus, 
AaLS-Switch-Red was used. A 10-fold excess of 0.4 M benzyl bromide (6 µL) was added 
to 4 mL of 1 mg/mL AaLS-Switch-Red and incubated at room temperature with gentle 
stirring for 1 hour. The reaction progress could not be colorimetrically monitored due to 
the lack of NTB. The sample was then dialyzed into ion exchange buffer A to remove 
excess unreacted benzyl bromide. 
4.4.10 Hydrogen Peroxide Treatment of the AaLS-Switch-Bz Capsid 
A 2 M H2O2 stock solution in lysis buffer B was prepared and used immediately. 
This was added to a 0.35 mg/mL solution of AaLS-Switch-Bz to a final concentration of 
10 mM. The reaction was incubated for 24 hours, at room temperature, in the dark, with 




of 20 mM. The sample was then immediately injected onto a HiPrep 16/60 Sephacryl S-
400HR column run with lysis buffer B at 4 °C.  
4.4.11 Mass Spectrometry of the Switch-Thiol Adducts 
Mass spectrometry was performed by the University of Utah Chemistry 
Department Mass Spectrometry Lab using a Waters LCT XE Premier ToF mass 
spectrometer. Samples were extensively dialyzed into nanopure water over the course of 
three days prior to being submitted for analysis.  
4.4.12 Treatment of Switch-Ox with DTT in Water 
 A 1 mg/mL sample of AaLS-Switch-Ox was dialyzed into nanopure water 
overnight at 4 °C with gentle stirring, in the dark. After dialysis, 1 M DTT was added to 
the sample to a final concentration of 10 mM. The sample was incubated at room 
temperature overnight. The DTT treated sample was then dialyzed into lysis buffer B 
overnight at 4 °C with gentle stirring, in the dark. The assembly state of the AaLS-
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